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https://doi.org/10.1016/j.celrep.2021.109375SUMMARYThemechanism of T cell antigen receptor (TCR-CD3) signaling remains elusive. Here, we identify mutations in
the transmembrane region of TCRb or CD3z that augment peptide T cell antigen receptor (pMHC)-induced
signaling not explicable by enhanced ligand binding, lateral diffusion, clustering, or co-receptor function. Us-
ing a biochemical assay and molecular dynamics simulation, we demonstrate that the gain-of-function mu-
tations loosen the interaction between TCRab and CD3z. Similar to the activating mutations, pMHC binding
reduces TCRab cohesion with CD3z. This event occurs prior to CD3z phosphorylation and at 0C. Moreover,
we demonstrate that soluble monovalent pMHC alone induces signaling and reduces TCRab cohesion with
CD3z in membrane-bound or solubilised TCR-CD3. Our data provide compelling evidence that pMHC bind-
ing suffices to activate allosteric changes propagating from TCRab to the CD3 subunits, reconfiguring inter-
chain transmembrane region interactions. These dynamic modifications could change the arrangement of
TCR-CD3 boundary lipids to license CD3z phosphorylation and initiate signal propagation.INTRODUCTION
T cell antigen receptor (TCR-CD3) signaling drives thymocyte
maturation and T cell responses upon recognition of highly poly-
morphic major histocompatibility complex (MHC) proteins pre-
sentingmyriadof shortpeptides (p) that originated from thedegra-
dation of self and foreign proteins (Stritesky et al., 2012). Despite
high physical and chemical diversity in binding interfaces, TCR-
CD3 ensures responses of exceptional specificity and sensitivity
(Davis et al., 2007), with weak affinity (0.1–100 mM) and short
half-life (t1/2) (<0.5 to several seconds) (Aleksic et al., 2012; Cole
et al., 2007; Stone et al., 2009). To accomplish this task, TCR-
CD3 uses a clonally distributed ab disulfide-linked dimer (TCR)
with immunoglobulin (Ig)-like variable domains Va and Vb. VaVb
forms a pMHC binding site of six loops homologous to antibody
complementaritydetermining regions (CDRs)1,2, and3 (GarbocziThis is an open access article undet al., 1996; Garcia et al., 1996). Germline-encoded CDR1 and
CDR2 have limited variability, whereas CDR3s are hypervariable.
VaVb orientates diagonally relative to the long axis of the peptide-
binding groove (Garboczi et al., 1996; Garcia et al., 1996), with
CDR3s contacting mainly the peptide and CDR1s and CDR2s
contacting mainly the MHC (Baker et al., 2012; Garcia et al.,
2012; Marrack et al., 2008). Va and Vb are connected to Ig-like
constant domains, namely, Ca and Cb, that are linked to the
transmembrane regions (TMRs) througha stalk, called connecting
peptide (CP). pMHC binding is signaled intracellularly by four
non-covalently associated subunits (g, d, ε, and z), called CD3,
organized into three dimers, namely, gε, dε and zz, with the latter
disulphide linked (Call et al., 2002). ε, g, and d exhibit an Ig-like
extracellular domain (ECD) connected to TMRs by short CPs,
whereas z features a z10-residue-long ECD. A recent TCR-
CD3 cryoelectron microscopy (cryo-EM) structure at 3.7 ÅCell Reports 36, 109375, July 13, 2021 ª 2021 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)






OPEN ACCESS(Dong et al., 2019) reconciles with mutational and nuclear mag-
netic resonance (NMR) studies (Call et al., 2002; He et al., 2015;
Mariuzza et al., 2020; Natarajan et al., 2016) but reveals other fea-
tures. VaVb projects forward with Ca interfacing with CD3d ECD,
Cb interfacing with both CD3gε and CD3d ECDs, and CD3g and
CD3ε (of dε) ECDs contacting each other. The TMRs of zz (z1z2)
and ab interact with each other, dε contacts a and z1, and gε
contacts b and z2. The highly interlaced structure suggests a
mutualistic contribution of each dimer to TCR-CD3 topology and
cohesion. The intrinsically disordered intracellular tails of ε, g,
d ,and z, invisible in the cryo-EM structure, contain immunorecep-
tor tyrosine-based activation motifs (ITAMs) that become phos-
phorylated by constitutively active Lck kinase (Nika et al., 2010)
within %1 s after pMHC binding (Acuto et al., 2008; Huse et al.,
2007). The tails are anchored to the plasma membrane (PM) by
basic amino acid residues and ITAM tyrosines that interact with
negatively charged lipids and hydrophobic lipid core, respectively
(Deford-Watts et al., 2009; Xu et al., 2008), perhaps preventing
ITAM access of unliganded receptors by Lck. Early studies sug-
gested that binding of agonist anti-CD3 antibody (Ab) induces
conformational changes in TCR-CD3 that expose CD3 cyto-
plasmic tails (Gil et al., 2002). However, crystallographic studies
of TCRab ECD found extensive conformational changes in
CDRs when bound to pMHC (Baker et al., 2012; Garcia et al.,
2012) but no unambiguous or consistent changes beyond the
TCRabbindingsite.This finding led tosuggestTCR-CD3signaling
models independent of conformational changes or in which
pMHCbindingwas insufficient to induceconformational changes.
Thesemodels posited that signaling is inducedby TCR-CD3 clus-
tering (Cochran et al., 2001; Yokosuka et al., 2005), co-receptors
(CD8/CD4) (Delon et al., 1998), or segregation of CD45 tyrosine
phosphatase (Davis and van der Merwe, 2006). Alternatively, me-
chanosensing-based models suggested that force generated by
PM movements acts on pMHC-bound TCR-CD3 to induce
conformational changes and signaling (Kim et al., 2009; Liu
et al., 2014). It was also proposed that TCR-CD3 clustering by
pre-existing pMHC dimers induces conformational changes in
CD3ε, but not directly in TCRab (Gil et al., 2002; Minguet et al.,
2007). Nevertheless, one crystal structure (Kjer-Nielsen et al.,
2003) and a fluorescence-based study (Beddoe et al., 2009)
showed that pMHC induced conformational changes in Ca.
Deuterium exchange (Hawse et al., 2012) andNMR investigations
(Natarajan et al., 2017;Rangarajanet al., 2018) inferredchanges in
conformational dynamics of soluble TCRab ECD when bound to
pMHC. These changes mapped to where Ca and Cb interfaceFigure 1. Gain-of-function mutations in b TMR
(A) CD3 surface expression of 1G4-WT and mutants. x ± SD of CD3+ cells, n = 3
(B) pErk response of 1G4-WT and b mutants stimulated with (6V-A2)4. x ± SEM o
(C) pErk response of CD8 J76 1G4-WT and 1G4-bA291 stimulated with (6V-A2)4
(WT), 0.89 (bA291); EC50 = 19.5 ± 5.5 (WT), 19.0 ± 3.1 (bA291). Right, x ± SD of m
(D) (6V-A2)4 binding to 1G4-WT or 1G4-bA291. Top, (6V-A2)4 dose-dependent as
(ns). Bottom, (6V-A2)4 dissociation rate, n = 5, non-linear regression fit, R
2 = 0.84
(E) pz response of J76 1G4-WT or 1G4-bA291 stimulated with (6V-A2)4. Left, non
(bA291). Right, x ± SD of max. pz, n = 4, unpaired t test p = 0.0078. See also Fig
(F) Basal pz in J76 1G4-WT or 1G4-bA291. pz MFI normalized to surface CD3 M
(G) FRAP of 1G4-WT or 1G4-bA291 treated (right) or not (left) with A770041. x ±
(H) Lateral distribution by dSTORM of 1G4-WT or 1G4-bA291 treated (right) or not
R 25 cells. Histograms show DBSCAN cluster analysis, x ± SD of cluster size pewith ECDs of CD3 subunits (He et al., 2015; Natarajan et al.,
2016). These studies could not rule in or out models proposed
thus far nor did they prove that allosteric effects propagate from
ab to the CD3 subunits for signaling to occur. To challenge this
impasse, we conceived a genetic perturbation analysis to help
discriminate between models requiring or not molecular flexibility
(i.e., conformational changes). Toward this goal, we questioned
the functional role of ab TMR that establishes a key physical
connection between the pMHC-binding module and the CD3
signaling subunits. If TMRs are only required for TCR-CD3 solva-
tionwithin the lipidbilayerandquaternary structure topology,TMR
mutations should not change TCR-CD3 intrinsic signaling capa-
bility. In contrast, this could happen inmechanisms based on allo-
steric interaction or force. We gathered compelling evidence for
TMR mutations in TCRb and CD3z that loosen quaternary struc-
ture cohesion and surprisingly augment signaling output. We
also found that soluble monomeric pMHC agonists reduce TCR-
CD3 quaternary structure cohesion and induce signal transduc-
tion, independently of co-receptor, clustering, or force. We
propose that allosteric activation of TCR-CD3 by pMHC binding
is the prime mover of T cell activation.
RESULTS
Gain-of-function mutations in b TMR
To question whether structural alterations in ab TMR affected
signaling, we used 1G4, an HLA-A2-restricted TCR specific for
the 157-165 peptide from the NY-ESO-1 tumor antigen (Chen
et al., 2005). Most residues of b TMR were individually replaced
by alanine or leucine and the corresponding mutants tested for
reconstituting TCR-CD3 surface expression in TCRb-deficient
Jurkat cells (J31.13) (Figure 1A). As reported earlier, bK287 mu-
tation drastically reduced TCR-CD3 surface expression (Alcover
et al., 1990). However, alanine substitutions at bY281, bL285,
bG286, bT289, bL290, bY291, and bS296 and leucine at bA292
showed only a z20%–40% decrease of surface expression.
Next, themajority of mutants showing 0%–40% reduction of sur-
face expression was co-expressed together with wild-type (WT)
1G4 TCRa in J31.13, and Erk activation (pErk) was monitored af-
ter stimulation with 6V-HLA-A2 tetramer (6V-A2)4 (Figure 1B).
Although no mutation significantly reduced Erk activation, both
bA290 and bA291 significantly increased pErk. A gain of function
was unexpected, even more so as bA290 and bA291 reduced
TCR-CD3 surface expression (data in Figure 1B are not normal-
ized for TCR-CD3 surface expression).–8. Ala (red) and Leu (blue) substitution.
f pErk+ cells; n = 3–6; unpaired t test, p = 0.0011 (bA290), p = 0.0092 (bA291).
. Left, non-linear regression fit of (6V-A2)4 nM versus pErk MFI, n = 3, R
2 = 0.82
ax. pErk, n = 3, F-test p < 0.0001. See also Figure S1E.
sociation, n = 3, non-linear regression fit, R2 = 0.98 (WT), 0.97 (bA291), F-test
(WT), 0.72 (bA291), F-test (ns).
-linear regression fit of (6V-A2)4 MFI versus pz MFI, n = 3, R
2 = 0.95 (WT), 0.96
ure S1F.
FI, n = 8, unpaired t test p < 0.0001. See also Figures S1H and S1I.
SD of diffusion coefficient, D (mm2/s), n R 20 cells, t test (ns).
(left) with A770041. Plots represent pair auto-correlation analysis (g), x ± SD of
r cell, t test (ns).
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To validate this apparently paradoxical observation, we focused
on bA291 and modified the experimental set up to improve data
robustness. Thus, a and b of 1G4 were expressed as a single
self-cleavable polypeptide (Figure S1A) from a doxycycline
(dox)-inducible promoter in a TCRab-deficient Jurkat cell line
(J76). J76 expressed maximum levels of surface TCR-CD3 after
16–18 h of dox treatment and were tested soon after to reduce
the potential risk of phenotypic drift of cells expressing 1G4 car-
rying bA291 (hereafter, referred to as 1G4-bA291). As in 31.13
cells, 1G4-bA291 expressed in J76 showed reduced surface
expression (z30%) (cf. Figure 1A with Figure S1B). However,
in most experiments, we lowered the dox concentration when
inducing 1G4-WT to reduce the difference in surface expression
with 1G4-bA291 (to <5%) (Figure S1C). Moreover, in most flow
cytometry analyses, J76 expressing 1G4-WT or mutant were
barcoded by labeling with CellTrace violet, mixed before stimu-
lation, and analyzed simultaneously. These stratagems simpli-
fied and made more robust the computation of differences in
signaling output between the WT and mutant. Erk activation
was retained as a sensitive and reliable readout of TCR-CD3
signal transduction and propagation as it depends on a cascade
of early signaling steps, including ITAMphosphorylation, ZAP-70
activation, LAT signalosome assembly, and PLCg1 activation
that generates IP3 (for intracellular [Ca
2+] increase) and DAG
required for Ras activation byRas-GRP (Acuto et al., 2008). Titra-
tion of (6V-A2)4 showed a shift in pErk response by 1G4-bA291
toward higher sensitivity and revealed significantly higher Erk
activation (Figure 1C). This result was not due to a higher Erk
activation ceiling in 1G4-bA291-expressing cells (Figure S1D)
nor to augmented binding of (6V-A2)4 to 1G4-bA291 (Figure 1D,
top and bottom panels), but it was consistent with the dose-
response plot showing unchanged EC50 between 1G4-bA291
and 1G4-WT (Figure 1C and STAR Methods for computation).
The higher maximal response of 1G4-bA291 was compatible
with a faster proofreading rate (kp) for a receptor operating in a
kinetic proofreading regimen (McKeithan, 1995). Indeed, fitting
the data of Figure 1C into a minimal model of kinetic proof-
reading (Dushek et al., 2011) showed that kp for 1G4-bA291
was considerably higher than that for 1G4-WT (Figure S1E),
consistent with bA291 enhancing TCR-CD3 intrinsic signaling
capability (i.e., higher ligand potency). The gain of function was
observed in CD8-deficient J76 (Figure 1C), ruling out that the
bA291 enhanced the TCR-CD3 interaction with co-receptor.
Augmented signaling was also evident for z phosphorylation
(pz) (Figures 1E and S1F), the earliest intracellular signaling
event. Remarkably, anti-CD3ε (UCHT1) Ab stimulation of 1G4-
bA291 also heightened pz (Figure S1G), a triggering modality
that by-passes pMHC binding, further supporting that bA291
enhanced TCR-CD3 signaling. These data suggested that
bA291 might increase constitutive TCR-CD3 signaling detected
by measuring pz in non-stimulated cells. Indeed, basal pz
was significantly higher in cells expressing 1G4-bA291 as
compared to 1G4-WT (Figures 1F and S1H), and it was TCR
signal specific as it disappeared after treatment by A770041
(Stachlewitz et al., 2005), a highly specific Lck inhibitor (Fig-
ure S1I). We then asked if bA291 increased signaling by influ-
encing TCR-CD3 lateral diffusion and/or distribution. However,4 Cell Reports 36, 109375, July 13, 2021fluorescence recovery after photo-bleaching (FRAP) found no
significant difference in the diffusion coefficient (D) between
1G4-bA291 and 1G4-WT (Figure 1G, left panel), which remained
unchanged after A770041 treatment (Figure 1G, right panel).
Direct stochastic optical reconstruction microscopy (dSTORM)
super-resolution microscopy found no statistically significant
difference in the cluster size distribution formed by 1G4-bA291
and 1G4-WT (histograms in Figure 1H). Although not statistically
significant, the reproducible small increase of larger cluster fre-
quency for 1G4-bA291 disappeared after A770041 treatment
(cf. auto-correlation function plots in left and right panels of Fig-
ure 1H), indicating it to be secondary to 1G4-bA291 heightened
basal signaling (Figure 1F) rather than bA291 causing it. Finally,
we questioned the potential cause(s) of mildly reduced 1G4-
bA291 surface expression. We excluded that bA291 reduced b
protein expression (Figure S1J) and considered that heightened
basal signaling might decrease receptor surface expression by
increasing its downregulation rate. However, exposure to
A770041 for several hours increased surface expression of
both 1G4-bA291 and 1G4-WT in a similar proportion (z20%)
but did not reduce their difference (Figure S1K). These data led
us to consider if bA291modified the stability of TCR-CD3 quater-
nary structure that could reduce export to the PM due to
increased negative triage by protein quality-control systems
(Feige and Hendershot, 2013) of mutant versus WT.
bY291 contribution to TCR-CD3 quaternary structure
cohesion
Non-ionic detergents used at a high concentration to quantita-
tively extract TCR-CD3 can dissociate TCRab from the CD3
modules (Testi et al., 1989). Presumably, this can be attributed
to extensive substitution of natural boundary lipids by the deter-
gent, with possible interference with TMR inter-helical interac-
tions critical for TCR-CD3 quaternary structure cohesion (Al-
cover et al., 1990; Call et al., 2002). However, 0.5% of the
non-ionic detergent n-dodecyl-b-D-maltopyranoside (DDM)
allows quantitative extraction of stoichiometrically intact TCR-
CD3 (Swamy et al., 2008; Figure S2A). Thus, if bA291 altered
TCRab cohesion with CD3 by unsettling TMR inter-helical inter-
actions, 0.5%DDMextractionmay show lower recovery of intact
1G4-bA291 with respect to 1G4-WT. Figure S2B illustrates the
experimental set up of chemically probing TCR-CD3 cohesion
by DDM that we named DDM stability assay (DSA) (see STAR
Methods for details). Membrane solubilisation by 0.5% DDM
and pull-down (PD) of total b (mostly associated with a; Alcover
et al., 2018) by the b-hemagglutinin (HA) tag was followed by
quantitative immunoblot (IB) for b (with anti-HA Ab) and for
each CD3 subunit. Anti-HA IB identified three b isoforms (named
b1, b2, and b3; Figure 2A). b3 was the endo-H-sensitive endo-
plasmic reticulum (ER)-resident b isoform (Figure S2C) that is
assembled with a, gε, and dε but not with zz (Alcover et al.,
2018), as confirmed by b3 being undetected in CD3z PD (Fig-
ure S2D). b1 and b2 were both endo-H-resistant (Figure S2C),
although b2 was the only b isoform associated with zz (Fig-
ure S2D). Thus, to evaluate the effect of bA291 on TCR-CD3
complex cohesion, we used the IB signals of b isoforms, namely,
zz and ε (which includes gε and dε). When z/b2 was set equal to 1
for 1G4-WT (i.e., 100% recovery of intact TCR-CD3), reduced
Figure 2. bY291 contribution to TCR-CD3quaternary struc-
ture cohesion
(A) Anti-HA (b-HA) pull-down (PD), and IB of 1G4-WT or 1G4-bA291.
Top panels: left, representative IB, arrows indicate b-isoforms; right,
x ± SD of ε/bT and z/b2, n = 5, unpaired t test p < 0.0001. Bottom
panels: input lysates, left, representative IB; right, x ± SD of bT/actin,
ε/actin and z/actin, n = 5, unpaired t test (ns).
(B) b-HA PD and IB of 1G4-WT or 1G4-bA291. NR (non-reducing)
conditions. Left, representative IB. Right, x ± SD of g/bT, n = 4,
unpaired t test p < 0.0001.
(C) b-HA PD and IB of 1G4-WT or 1G4-bA291. NR conditions. Left,
representative IB. Right, x ± SD of d/bT, n = 4, unpaired t test p <
0.0001.
(D) All-atom MDS of TCR-CD3 TMRs. TCRa (ochre), TCRb (gray),
CD3d (blue), CD3ε (yellow), CD3g (green), z (red). Left, snapshot of
TCR-CD3 TMRs. Right, bY291 interactions with TCR-CD3 TMRs.
Liquorice sticks show significant contacts of bY291 with TCRa,
CD3g, and CD3ε. See also Figure S2H.
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OPEN ACCESScohesion between zz andab should result in z/b2 < 1 (Figure S2B).
The DSA showed that z/b2 for 1G4-bA291 was 0.2, indicating
only 20% recovery of intact TCR-CD3 (or 80% loss of zz recov-
ery) after DDM solubilization (Figure 2A). To determine the effect
of bA291 on gε and dε cohesionwith ab, we used instead the sum
of b1, b2, and b3 (total b (bT) IB signals that represented cyto-
plasmic and PM ab, of which most is associated with ε (Alcover
et al., 2018). ε/bT for 1G4-bA291 was 0.5, indicating 50%
reduced recovery of ε (Figure 2A). These ratios did not change
after A770041 treatment during dox induction of ab expression
(Figure S2E), excluding that reduced recovery concerned the
pool of 1G4-bA291 with increased basal pz (Figure 1F). The
considerable reduction of z (80%) and ε (50%) recovery for
1G4-bA291 could not be the consequence of severance of the
same magnitude of ab from zz (or from dε and gε) before export
to the PM and/or at the PM, as only 20%–30% reduction of TCR-
CD3 expression was observed by flow cytometry and incompat-
ible with increased pMHC-induced signaling. Indeed, when
TCRab is no longer in contact with zz, TCRabdεgε alone cannot
be exported to the T cell surface (Figure S2F; Alcover et al.,
2018). Therefore, in the PM natural lipid environment, bA291
only slightly perturbed TCR-CD3 quaternary structure cohesion
(as the molecular dynamics simulations [MDSs] show, see
below), moderately reducing surface expression. However, sub-
stitution of natural boundary lipids by DDM severely corroded
TCR-CD3 cohesion in 1G4-bA291 and provoked partial physical
detachment of z and ε from ab during the solubilization. IB for g
and d revealed that bA291 affected both gε and dε cohesion with
the rest of the complex, although asymmetrically, as it reduced
gε and dε recovery of 40% and 10%, respectively (Figures 2B
and 2C). In the cryo-EM structure, bY291 (note that Dong et al.
2019 refer to bY291 as bY292) contacts mostly gε, and therefore,
bA291 can be expected to primarily affect the interaction be-
tween ab and gε in accordance with the DSA. However, bY291
makes no contacts with zz and dε (Dong et al., 2019) (see MDS
below). Therefore, the DSA revealed a more complex picture,
with bA291 presumably indirectly affecting the interaction of
both zz and dεwith the rest of the complex. To further understand
the structural role of bA291, we used the TMR atomic coordi-
nates of the cryo-EM structure of the TCR-CD3 octamer (PDB:
6JXR) (Dong et al., 2019) to carry out all-atom MDSs with bWT
and bA291 in an asymmetric lipid bilayer, mimicking the lipid
environment of TCR-CD3, thus adding dynamical insight intoFigure 3. Loosening z association enhances signaling
(A) TCR-CD3 expression of 1G4-WT, 1G4-bA291, 1G4-bL291, and 1G4-bF291 in
0.0001. Right, x ± SEM of b-HA MFI in HAlowgate, n = 3, t test (ns).
(B) b-HA PD and IB of 1G4-WT or 1G4-bmutants. Left, representative IB, the arro
bA291, WT versus bL291 p < 0.0001, WT versus bF291 p < 0.01. Right, x ± SD o
(C) pErk response of CD8 J76 1G4-WT or 1G4-bF291 stimulated with (6V-A2)4.
(WT), 0.910 (bF291). Right, x ± SD of max. pErk, n = 3, F-test p < 0.05. See also
(D) pErk response of CD8 J76 1G4-WT or 1G4-bL291 stimulated with (6V-A2)4. L
(WT), 0.910 (bL291). Right, x ± SD of max. pErk, n = 3, F-test p < 0.0001. See al
(E) TCR-CD3 expression in CD8 J76 2H5-WT or 2H5-bA291. Left, x ±SEM of CD
in HAlowgate, n = 3, t test (ns).
(F) b-HA PD and IB of 2H5-WT or 2H5-bA291. Left, representative IB. Middle, x ± S
test p < 0.01.
(G) pErk response of CD8 J76 2H5-WT or 2H5-bA291 stimulated with (MART-1-
R2 = 0.94 (WT), 0.94 (bA291). Right, x ± SD of max. pErk, n = 3, F-test p < 0.001TCR-CD3 cohesion. Simulations for 1,250 ns confirmed consid-
erable contacts of bWT with ε (of gε), g, a, and zz but not with
dε (Figures 2D and S2G) and revealed one new contact of b
with zz as well as significant reduction in six b contacts with ε
(gε), five with g, and four with a (Figure S2G). Specifically, signif-
icant contacts were observed of bY291 with aN263, aT267,
gL129, gG132, and εL145 (Figures 2D, right panel, and S2H)
and with gV133 and gI136, although the latter two were not sig-
nificant (Figure S2H). No contacts of bY291 with zz were seen
(Figure S2G). Simulations of the TMR octamer carrying bA291
indicated new and augmented contacts of b with ε (gε) and g
(Figure S2I). In addition, although bA291 still contacted gL129,
it completely lost interaction with gG132, gV133, and gI136 (Fig-
ure S2J, middle panel). Likely, these changes were secondary to
spatial re-adjustments due to the loss of the bulky tyrosine side
chain. No contacts of bA291 with zz were observed. Overall, the
simulations suggested that bA291 reshuffled contacts with gε,
with the net effect of increasing local compaction (Figure S2K),
as indicated by a stabilization of their a helix crossing angle (Fig-
ure S2L). This result seemed to contradict the DSA data of bA291
severely affecting the zz interaction with the rest of the complex.
Although a 1,250-ns timescale is relatively long for all-atom sim-
ulations of membrane proteins, it might be insufficient to capture
re-adjustments of interchain contacts that possibly occur at
larger timescales. bA291 might affect the role of interfacial lipids
in cementing a helix interactions (Gupta et al., 2017) that, when
challenged with DDM, might cause crumbling of TMR cohesion
in the mutant, despite augmented compaction by bA291 else-
where. However, reduced export to the PMwas a good indicator
that bA291 (and other b and zTMR mutants, see below) pro-
moted some instability of the complex, causing dynamical expo-
sure of hydrophobic site and/or retention signals, detected and
negatively triaged by protein quality-control systems (Feige
and Hendershot, 2013). Comprehensively, these data suggested
a positive correlation between TCR-CD3 reduced quaternary
structure cohesion and activation of signal transduction.
Loosening z association enhances signaling
To corroborate this hypothesis, we investigated the phenotype of
additional mutations in b and z TMRs. We found that similar to
bA291, also bF291 and bL291 mildly reduced TCR-CD3 surface
expression, despite no decrease in b expression (Figure 3A).
Bothmutations reduced the interactionofbwithzandε (Figure3B)CD8 J76. Left, x ± SEM of CD3 MFI in HAlowgate, n = 3, unpaired t test p <
w indicates b2 isoform. Middle, x ± SD of z/b2, n = 3, unpaired t test WT versus
f ε/bT, n = 3, unpaired t test p < 0.0001.
Left, non-linear regression fit of (6V-A2)4 nM versus pErk MFI, n = 3, R
2 = 0.915
Figure S3A (left).
eft, non-linear regression fit of (6V-A2)4 nM versus pErk MFI, n = 3, R
2 = 0.827
so Figure S3A (right).
3MFI in HAlowgate, n = 3, unpaired t test p < 0.0001. Right, x ±SEM of b-HAMFI
D of z/b, n = 3, unpaired t test p < 0.0001. Right, x ± SD of ε/b, n = 3, unpaired t
A2)4. Left, non-linear regression fit of (MART-1-A2)4 nM versus pErk MFI, n = 3,
. See also Figure S3B.
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OPEN ACCESSand augmented pErk maximal response to (6V-A2)4 (Figures 3C
and3D), whosebinding remainedunchanged (FigureS3A). These
three readouts ranked according to bL291 R bA291 > bF291 >
WT, presumably reflecting conservative or non-conservative re-
placements, and hence indicating a direct correlation between
increased quaternary structure loosening and heightened
signaling. We then tested the effect of bA291 in 2H5, a HLA-A2-
restricted TCR specific for the MART-1 tumor antigen (Circosta
et al., 2009). Similar to 1G4-bA291, 2H5-bA291 showed reduced
surfaceexpression (Figure3E) andTCR-CD3cohesion (Figure3F)
and augmented pErk for equal (MART-1-A2)4 binding (Figures 3G
andS3B). Conversely,mutation of b TMR residues not involved in
critical contacts (Dong et al., 2019), such as bA293 and bA303,
showed no significant change of 1G4 surface expression (Fig-
ure S3C) or TCR-CD3 cohesion (Figures S3D and S3E) and no in-
crease in (6V-A2)4-induced pErk (Figures S3F and S3G).
bY291 did not contact z, but its mutation augmented basal
(Figure 1F) and ligand-induced pz (Figure 1E) and signal propa-
gation. This was reminiscent of an allosteric interaction revealed
by mutations (Changeux and Christopoulos, 2016; Volkman
et al., 2001), e.g., bA291 inducing local re-adjustments but also
distal functional effects, such as favoring exposure of z cytosolic
tail to active-Lck. To investigate this possibility, we tested
whether mutations in z TMR residues susceptible to loosen zz
contacts with subunits other than ab phenocopied mutations
at bY291. TCR-CD3 cryo-EM structure and MDS indicated that
z1 and z2 TMRs contacted only the N-terminal moiety of b TMR
(Figures 4A and S4A) and a TMR throughout (Figures 4B and
S4B). However, z2 and z1 also contacted g (Figures 4C and
S4C) and ε (of the dε) (Figures 4D and S4D), respectively. Specif-
ically, MDS revealed that z1I38 contacted two residues of ε (of dε)
(Figures 4D and S4E, left panel) and z2I41 contacted two resi-
dues of g (Figures 4C and S4F, left panel), whereas z2I38 and
z1I41 bulged toward the membrane lipids and made no contact
with the complex. Thus, z1I38 and z2I41 were deemed capable
of partially disturbing z1 and z2 interactions with ε (of dε) and g
but perhaps not with ab. To verify this prediction, 1,250 ns all-
atom simulations of TCR-CD3 octamer TMRs composed of z
WT and zA41 and zA38 mutants were carried out. At the end of
the simulations, snapshot alignment of the mutated and WT
TMRs showed distortion in the contacts of z1 with dε (Figure 4E)
and z2 with g (Figure 4G). As a consequence, zz containing z1A38
(3 out of 3 simulations) or z2A41 (2 out of 3 simulations) increasedFigure 4. Loosening z association enhances signaling
(A) Snapshot from all-atom MDS of TCR-CD3 TMRs. Contacts between TCRb
represented as liquorice stick for reference and does not contact zz.
(B) Snapshot from all-atom MDS of TCR-CD3 TMRs. Left, z1 (light red) and z2 (da
residues contacting z1 and z2 TMRs (in transparency). See also Figure S4B.
(C) Snapshot from all-atom MDS of TCR-CD3 TMRs. Left, contacts between z2 (r
(green). See also Figures S4C and S4F.
(D) Snapshot from all-atomMDS of TCR-CD3 TMRs. Left, contacts between z1 (re
(dε) (yellow). See also Figures S4D and S4E.
(E) Snapshot from all-atom MDS of TCR-CD3 TMRs carrying zA38 (lines) aligned
(blue), CD3ε (yellow), CD3g (green), z (red). See also Figures S4G–S4J.
(F) Normalized spatial distributions of the Ca atoms of zz relative to the Ca atom
(G) Snapshot from all-atom MDS of TCR-CD3 TMRs carrying zA41 (lines) aligned
(blue), CD3ε (yellow), CD3g (green), z (red). See also Figures S4K–S4N.
(H) Normalized spatial distributions of the Ca atoms of zz relative to the Ca atomfluctuation relative to ab as compared to zz WT. This can be
appreciated from the average spatial distribution plots of the
Ca atoms of zz relative to the Ca atoms of ab that showed
broader density for both mutants (Figures 4F and 4H), although
this was more pronounced for z1A38. These results were indica-
tive of zA38 and zA41 increasing zz flexibility relative to ab. Both
mutants maintained some zz contacts with the rest of the com-
plex (Figures S4G–S4N). These results prompted us to test if,
similar to the bA291 mutations, these z mutations also showed
reduced surface expression, complex cohesion by DSA, and
enhanced signaling. The data showed that zA38 or zA41 reduced
1G4 surface expression by z30%, for similar z expression (Fig-
ure 5A). The DSA showed that zA38 and zA41 reduced the z/b2
ratio to z0.05 and z0.25 (95% and 75% loss of z recovery)
respectively, without apparently affecting ε cohesion with ab.
(Figures 5B and S5A). Thus, the DSA agreed with loosening of
the zz interaction with ab as predicted by the atomistic simula-
tions. Perhaps, weakening direct interactions with CD3 TMRs
and causing higher zz mobility, zA38 and zA41 indirectly weak-
ened the zz interaction with ab as well, as revealed by DDM
extraction. Simulations of larger timescales may provide clearer
insights into dynamic alterations of zz by bA291 producing direct
effects on gε and later indirect ones on zz. Importantly, similar to
bA291, both z mutations conferred to 1G4 heightened the pErk
response to (6V-A2)4, with a higher maximum than that of 1G4-
WT (Figures 5C and 5D) for equal (6V-A2)4 binding (Figures
S5B and S5C). We concluded that reduced cohesion between
ab and zz caused heightened signaling, rather than themutations
of bY291 per se. This conclusion strengthened the idea that
reducing TCR-CD3 cohesion populated the active signaling
state of TCR-CD3, i.e., it lowered the activation energy between
two presumed functional states, inactive and active, with the
latter initiating transmembrane signaling. These data made it un-
likely that TCR-CD3 TMRs are just structural elements required
for TCR-CD3 membrane solvation and architecture, as confor-
mational change-independent models would imply. Rather, by
analogy with allosterically regulated proteins that can be
switched on or off by mutations distal from their active site(s)
(Changeux and Christopoulos, 2016; Volkman et al., 2001) and
considering recent NMR studies (He et al., 2020; Natarajan
et al., 2016, 2017; Rangarajan et al., 2018), our data suggested
that pMHCbinding activated an allosteric cascade that loosened
TCR-CD3 cohesion, including interactions with zz TMRs serving(gray), z1 (light red), and z2 (dark red) TMRs. See also Figure S4A. bY291 is
rk red) residues contacting TCRa TMR (in transparency). Right, TCRa (ochre)
ed) and CD3g (green) TMRs. Right, top view of z2I41 (red) contacts with CD3g
d) and CD3ε (dε) (yellow) TMRs. Right, top view of z1I38 (red) contacts with CD3ε
to zWT (cartoon) at the end of 1,250 ns MDS. TCRa (ochre), TCRb (gray), CD3d
s of TCRab in zWT and zA38.
to zWT (cartoon) at the end of 1,250 ns MDS. TCRa (ochre), TCRb (gray), CD3d
s of TCRab in zWT and zA41.
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Figure 5. Loosening z association enhances
signaling
(A) TCR-CD3 expression in J76-1G4WT-zKO ex-
pressing zWT or zA38 or zA41. Left, x ± SEM of
CD3 MFI in HAlow gate, n = 3, unpaired t test p <
0.0001. Middle, representative IB. Right, x ± SD of
z/actin, n = 3, unpaired t test (ns).
(B) b-HA PD and IB of 1G4-WT carrying zWT or
zA38 or zA41. Left, representative IB, the arrow
indicates b2 isoform. Middle, x ± SD of ε/bT, n = 4,
unpaired t test (ns). Right, x ± SD of z/b2, n = 4,
unpaired t test p < 0.0001. See also Figure S5A.
(C) pErk response of J76-1G4WT-zKO expressing
zWT or zA38 stimulated with (6V-A2)4. Left, non-
linear regression fit of (6V-A2)4 nM versus pErk
MFI, n = 3, R2 = 0.98 (WT), 0.99 (zA38). Right, x ±
SD of max. pErk, n = 3, F-test p < 0.0001. See also
Figure S5B.
(D) pErk response of J76-1G4WT-zKO expressing
zWT or zA41 stimulated with (6V-A2)4. Left, non-
linear regression fit of (6V-A2)4 nM versus pErk
MFI, n = 3, R2 = 0.96 (WT), 0.97 (zA41). Right, x ±




OPEN ACCESSas a second-to-last relay before licensing z ITAM phosphoryla-
tion. These considerations prompted us to investigate this
possibility.
pMHC tetramer binding loosens ab association with z
Conformational changes produced by pMHC binding may have
distal effects that reduce contacts of CaCb with dε and/or gε
ECDs, eventually propagating to TMR contacts, including zz
TMR, and resulting in reduced TCR-CD3 cohesion. If correct,
the DSA should show reduced recovery of zz in ligand-engaged
TCR-CD3 versus unengaged TCR-CD3. To test this idea, we
aimed to capture DDM-solubilized pMHC-engaged TCR-CD3
and compare subunit recovery with unengaged TCR-CD3.
Thus, 1G4-WT-expressing J76 was briefly stimulated with (9V-
A2)4, tetramerized with His-tagged streptavidin [(9V-A2)4-His]
(Figure S6A), ligand excess was removed, and cells rapidly solu-
bilizedwith 0.5%DDM.Post-nuclear lysateswere incubatedwith
His-Cobalt beads for capturing (9V-A2)4-His-bound 1G4. This
experimental setting failed to capture sufficient (9V-A2)4-His-
bound TCR-CD3, likely because detergent solubilization inter-
fered with the avidity gain due to tetramer-induced clustering in
the membrane milieu, by making the dissociation rate of individ-
ual 9V-A2 in the tetramer closer to that of a 9V-A2monomer alone
(i.e., solution koff of 0.33 s
1 at 25C; Aleksic et al., 2010). To over-
come this limitation, we initially used wtc51 (Irving et al., 2012), a
1G4 variant harboring four mutations in bCDR2 (Figure S6B) that
confer a 15 nM diffusion constant (Kd) for NY-ESO-1157-165-HLA-
A2 (koff of 0.0013s
1 at 25C). Computational modeling showed
that NY-ESO-1157-165-HLA-A2 adopts a canonical orientation10 Cell Reports 36, 109375, July 13, 2021ontowtc51 VaVb, which is almost indistin-
guishable from 1G4-WT (Figure S6B). (9V-
A2)4-His induced robust wtc51-mediated
Erk activation (Figure 6A, left panel) andal-
lowed specific capture of engaged wtc51(Figure 6A, middle panel, lanes 2 and 4) to be compared with un-
ligandedwtc51 isolatedbyanti-HAbPD (Figure 6A,middlepanel,
lanes1 and3).b2was theonly isoformbound to (9V-A2)4-His (Fig-
ure 6A, middle panel, lanes 2 and 4), consistent with it being the
only one associated to z and present at the cell surface (Fig-
ure S2D). Therefore, the z/b2 ratio was used to assess if pMHC
binding had reduced cohesion of z within TCR-CD3 (Figure 6A,
right panel). The data showed that z/b2 in liganded wtc51 was
0.5 (Figure 6A, right panel), in agreement with pMHC binding
causing relaxation of TCR-CD3 cohesion. This effect was inde-
pendent of pz, as identical results were obtained after A770041
treatment (Figure 6A middle and right panels). Allosteric interac-
tion typically occurs in tens of ms to fewms (Volkman et al., 2001),
similar to the timescale observed by NMR for pMHC binding to
induce conformational changes in Cb (Natarajan et al., 2017).
As pMHC binding dwell times are of a much longer timescale
(e.g., hundreds of ms to min), allosterically induced conforma-
tional changes should be observable at non-physiological lower
temperatures. Consistently, almost identical reduction of the
z/b2 ratio was observed when (9V-A2)4 was reacted with cells
at 0C (Figure 6Bmiddle and right panels). Toexclude that ourob-
servations were biased by the particular mutations introduced in
bCDR2and/or by the non-physiological affinity ofwtc51,weused
QM-a TCR, a 1G4 variant carrying mutations in aCDR2, bCDR2,
and bCDR3 (Figure S6B; Irving et al., 2012), which confer a
140 nM Kd (koff, 0.015 s
1 at 25C) for NY-ESO-1157-165-HLA-A2
(Irving et al., 2012), within the physiological range of TCR-
pMHC binding affinity (Aleksic et al., 2012; Cole et al., 2007,
2017; Stone et al., 2009). Molecular modeling showed that
(legend on next page)






OPEN ACCESSQM-a and 1G4-WT have superimposable canonical orientation
whenbound toNY-ESO-1157-165-HLA-A2 (Figure S6B). Figure 6C
showed that binding of (9V-A2)4-His to QM-a induced strong Erk
activation (Figure 6C, left panel) and reduced z/b2 ratio (40%),
which remained unchanged after A770041 treatment (Fig-
ure S6C). These observations were extended to 868, a TCR iso-
lated from an HIV elite controller (Varela-Rohena et al., 2008).
868 recognizes the spontaneouslymutatedHIV p17Gag-derived
peptide SLYNTIATL (6I) presented by HLA-A2, with aKd of 53 nM
(koff, 0.0013s
1 at 4C; Cole et al., 2017). Being a natural TCR
directed at a viral antigen, 868 was ideal to validate the data ob-
tainedwith in-vitro-modified TCRs against a tumor antigen. Bind-
ing of tetramerized ligand (6I-A2)4-His stimulated strong Erk acti-
vation (Figure 6D, left panel) and weakened 868 quaternary
structurecohesion, asshownby the reduced z/b2 ratio (Figure6D,
middle and right panels). The occurrence of the same effect (i.e.,
structural changes) in three different TCRs by mere coincidence
is highly unlikely but rather the consequence of the same cause,
namely, ligand-induced conformational changes thatmodify crit-
ical contacts maintaining TCR-CD3 complex cohesion (Alcover
et al., 1990; Call et al., 2002; Dong et al., 2019). Reduced z cohe-
sion was also observed in wtc51 when expressed in primary hu-
man T cells stimulated with (9V-A2)4-His (Figure 6E), excluding
non-physiological behavior of TCR-CD3 in the PMof Jurkat cells.
To date, it remains unclearwhether anti-CD3εAbs used in clinical
settings activate TCR-CD3 by mechanisms distinct from that of
pMHC. To address this question, we slightly modified the DSA
(STAR Methods). We used monobiotinylated Fab’ of UCHT1
anti-CD3ε as a proxy for minimally or non-stimulated receptor
and monobiotinylated UCHT1 Ab to stimulate and capture
TCR-CD3 with streptavidin for IB analysis. Because TCR-CD3
was captured by CD3ε, b/ε and z/ε ratios were used to assess
TCR-CD3 cohesion. UCHT1 Ab binding reduced b/ε and z/ε ra-
tios and hence the cohesion of ε with b but less so with z (Fig-
ure 6F). Similar observations were made in cells pre-treated
with A770041 (Figures 6G and S6D) or reacted with UCHT1 at
0C (Figures 6H and S6E). Taken together, these observations
and the TMR mutant phenotype strongly suggested that TCR-
CD3 signals intracellularly by an allosteric interaction propa-
gating from the abbinding site to theCD3 subunits andmodifying
critical contacts within the TMRs.Figure 6. pMHC tetramer binding loosens ab association with z
(A) J76 wtc51 stimulated with (9V-A2)4-His ±A770041. Left, representative pErk IB
(lanes 2, 4, 6) followed by IB for b and z. Blocking was with HA peptide or imidazo
p < 0.0001.
(B) J76 wtc51 stimulated with (9V-A2)4-His at 0
C. Left, representative pErk IB (n =
indicates b2 isoform. Right, x ± SD of z/b2, n = 4, unpaired t test p < 0.0001.
(C) J76 QM-a stimulated with (9V-A2)4-His. Left, representative pErk IB (n = 3).
indicates b2 isoform. Right, x ± SD of z/b2, n = 3, unpaired t test p < 0.01.
(D) J76 868 stimulatedwith (6I-A2)4-His. Left, representative pErk IB (n = 3). Middle
isoform. Right, x ± SD of z/b2, n = 3, unpaired t test p < 0.01.
(E) Primary T cells expressing wtc51 stimulated with (9V-A2)4-His. Left, represent
and z. The arrow indicates b2 isoform. Right, x ± SD of z/b2, n = 3, unpaired t tes
(F) J76 1G4 ± UCHT1-Fab’ or UCHT1-Ab. Left, streptavidin (SA)-mediated PD and
p < 0.0001.
(G) J76 1G4 ± A770041 incubated or not with UCHT1-Fab’ or UCHT1-Ab. Left, SA
test p = 0.0007, p = 0.0494. See also Figure S6D.
(H) J76 1G4 ± UCHT1-Fab’ or UCHT1-Ab at 0C. Left, SA-mediated PD and IB fo
0.0218. See also Figure S6E.
12 Cell Reports 36, 109375, July 13, 2021Soluble monovalent pMHC triggers TCR-CD3 untying
and intracellular signaling
pMHC tetramers induced conformational change and signaling
without force. However, pMHC tetramers necessarily induced
fast TCR-CD3 clustering and therefore cannot allow to discern
if receptor aggregation was responsible for allosteric activation,
as previously suggested (Minguet et al., 2007). We therefore re-
acted wtc51-expressing J76 with biotinylated soluble monova-
lent (sm)-9V-A2 (Figure 7A). Monodispersion of (sm)-9V-A2
was controlled by size-exclusion chromatography-multi-angle-
light scattering (SEC-MALS), just before use (Figure S7B, only
fractions within the sm-9V-A2 peak were used). Following
DDM solubilization, sm-9V-A2-bound TCR-CD3 was captured
by His-streptavidin/His-Cobalt beads (Figure S7A) and z recov-
ery examined. The z/b2 ratio was considerably reduced in sm-
9V-A2-bound versus unbound wtc51 and was unaffected by
A770041 treatment (Figure 7A, IBs and histograms) or by the
absence of the CD8 co-receptor (Figure 7B). To definitively
exclude potential sm-pMHC cross-linking after solubilization
by streptavidin used for capturing ligand-bound TCR-CD3, we
used instead a monomeric Avidin (mAv). However, this condition
did not change the result (Figure S7D). A similar z/b2 reduction
was observed for 868 TCR reacted with soluble monodispersed
sm-6I-A2 (Figures 7C for DSA and Figure S7C for SEC). Figure 7E
(IBs and histograms) shows that sm-9V-A2 reduced z recovery
also inwtc51 expressed in primary T cells, excluding a bias of Ju-
rkat cell PM. A more stringent test for TCR-CD3 allosteric regu-
lation was to assess whether sm-pMHC promotes quaternary
structure untying after solubilization. sm-9V-A2 bound to wtc51
TCR at 0C in post-nuclear lysates with 0.5% DDM, as revealed
by streptavidin IB (Figure S7E), considerably reduced the z/b2 ra-
tio (Figure 7F). Thus, TCR-CD3 loosening by pMHC binding did
not require intact PM, and as it should be expected for an allo-
steric change, it relied essentially on protein-protein interactions.
Moreover, because it occurred in isolated TCR-CD3, these data
further corroborated the idea that the allosteric changewas inde-
pendent of force, clustering, and co-receptor. If the conforma-
tional change induced by sm-pMHC was functionally relevant,
it should also induce intracellular signaling. Previous work
could not demonstrate that binding of sm-pMHC in solution eli-
cited a [Ca2+]i increase unless the co-receptor was expressed(n = 4). Middle, PDwith anti-HA Ab (HA) (lanes 1, 3, 5) or His-Cobalt beads (His)
le. The arrow indicates b2 isoform. Right, x ± SD of z/b2, n = 5–6, unpaired t test
4). Middle, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b and z. The arrow
Middle, b-HA (lanes 1, 4) or His (lanes 2, 3) PD and IB for b and z. The arrow
, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b and z. The arrow indicates b2
ative pErk IB (n = 3). Middle, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b
t p < 0.001.
IB for b, z, and ε. Right, x ± SD of b/ε and z/ε, n = 4, unpaired t test p = 0.0023,
-mediated PD and IB for b, z ,and ε.Right, x ± SD of b/ε and z/ε, n = 3, unpaired t
r b, z and ε. Right, x ± SD of b/ε and z/ε, n = 3, unpaired t test p < 0.0001, p =
Figure 7. Monovalent pMHC in solution triggers TCR-CD3 untying and intracellular signaling
(A) J76 wtc51 ± A770041 stimulated or not with sm-9V-A2 were lysed and subjected to PD with anti-HA Ab or Talon beads. First panel, anti-HA (b-HA) (lanes 1, 3,
5) or Talon beads (His) (lanes 2, 4, 6) PD and IB for b and z. The arrow indicates b2 isoform. Second panel, x ± SD of z/b2, nR 3, unpaired t test p < 0.0001 and p <
0.01. Third panel, representative pErk IB. Fourth panel, x ± SD of pErk, n R 3, unpaired t test p < 0.0001.
(B) CD8 J76 wtc51 stimulated or not with sm-9V-A2 were processes as in (A). First panel, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b and z. The arrow
indicates b2 isoform. Second panel, x ±SD of z/b2, n = 3, unpaired t test p < 0.01. Third panel, representative pErk IB. Fourth panel, x ±SD of pErk, n = 3, unpaired t
test p < 0.05.
(legend continued on next page)






OPEN ACCESS(Delon et al., 1998). However, we found that sm-9V-A2,
controlled by SEC-MALS for being monodispersed (Figure S7B),
did induce robust pErk in both CD8-efficient (Figure 7A) and
CD8-deficient (Figure 7B) J76 cells expressingwtc51 and erased
by A770041 (Figure 7A). Erk activation by sm-9V-A2 was dose
dependent (Figure S7F), with as little as 3 nM inducing 50% of
the maximum and occurred at 2 min after sm-9V-A2 addition
(Figure S7G), similar to (9V-A2)4 stimulation of 1G4-WT (Paster
et al., 2015), although (9V-A2)4 generally induced a stronger
pErk response. We obtained similar data with 868 in the pres-
ence or absence of a CD8 co-receptor (Figures 7C, 7D, and
S7C) and with QM-a without CD8 (Figure S7H). Non-specific
adsorption of sm-pMHC onto the J76 cell membrane during
the stimulation assay was negligible even at the highest sm-
9V-A2 concentration (Figure S7I). This made it unlikely that
signaling was the consequence of sm-9V-A2 non-specific
adsorption to the cell surface and ligand cross-presentation
rather than direct stimulation by soluble sm-9V-A2. Moreover,
we experimentally tested whether even this negligible amount
of non-specifically bound sm-9V-A2 on J76 cells could be stim-
ulatory. However, we did not detect any Erk activation (Fig-
ure S7J). Multiple reasons can explain why our data apparently
conflict with previous observations. First and foremost, we
used TCRs of reduced koff (higher-affinity range) for pMHC,
including a natural one (868). sm-pMHC ligands of low-medium
affinity range (mM) can be expected to induce low/non-sustained
[Ca2+]i increase, whose ramp-up requires a complex cascade of
additional events (Irvine et al., 2002; Lewis, 2020), including co-
receptor implication (Delon et al., 1998; Minguet et al., 2007).
Also, sm-pMHC engages TCR-CD3 without immediately clus-
tering it, contrary to pMHC tetramers that provide this critical
signaling-reinforcing effect (see Discussion). Moreover, mem-
brane-tethered pMHC has lower degree of freedom than soluble
pMHC, a property that sensibly increases pMHC on-rate (Huppa
et al., 2010; O’Donoghue et al., 2013). Comprehensively, our ge-
netic, biochemical, MDS, and functional data constitute sub-
stantial evidence that TCR-CD3 is a genuine allosteric device.
We name this model ‘‘TCR-CD3 allosteric relaxation’’ (Fig-
ure S7K) as a mechanism sufficient to incite initial T cell activa-
tion solely by pMHC binding.
DISCUSSION
To gather insight into TCR-CD3 signaling, we used a genetic
perturbation approach and found that TMR mutations that loos-
ened cohesion between TCRab and CD3z increased the ago-
nist’s potency. This phenotype mimicked pMHC agonist binding
that also reduced cohesion between TCRab and CD3z. These(C) J76 868 stimulated or not with sm-6I-A2 were processed as in (A). First panel,
isoform. Second panel, x ± SD of z/b2, n = 3, unpaired t test p < 0.01. Third panel,
0.0001.
(D) CD8 J76 868 stimulated or not with sm-6I-A2. Left, representative pErk IB.
(E) Primary T cells expressing wtc51 stimulated or not with sm-9V-A2were process
The arrow indicates b2 isoform. Second panel, x ± SEM of z/b2, n = 2, unpaired t te
n = 2, unpaired t test p < 0.0001.
(F) J76 wtc51were lysed, incubated or not with sm-9V-A2 ,and subjected to PD by
and z. The arrow indicates b2 isoform. Right, x ± SD of z/b2, n = 5, unpaired t tes
14 Cell Reports 36, 109375, July 13, 2021convergent results suggested that weakening of TCR-CD3
TMR contacts is a key step in an allosteric mechanism initiated
by pMHC binding and culminating in ITAM phosphorylation.
We favor the idea that conformational changes occurring upon
pMHC binding propagate to CaCb ECDs, where they contact
the CD3 subunits (Beddoe et al., 2009; He et al., 2020; Natarajan
et al., 2017; Rangarajan et al., 2018). The ECDs and TMRs of
TCRab, CD3dε, and CD3gε show an extended intra-dimer inter-
face (Dong et al., 2019). Moreover, CD3dε and CD3gε interact
much more with TCRab than with each other. It is therefore
conceivable that pMHC binding induces reshuffling of contacts
between ECD dimers, loosening CD3dε and CD3gε from TCRab.
This may result in slight rotation and/or translation of CD3dε and/
or CD3gε vis-à-vis TCRab. The mechanical rigidity of ε, d, and g
CPs (Alcover et al., 2018) could transmit thesemovements to the
respective TMRs, resulting in local rearrangements of helix-helix
packing and perhaps of interfacial lipids (Gupta et al., 2017; Fig-
ure S7K). Consistently, mutations of ε Cys-Cys loop affect TCR-
CD3 signaling (Wang et al., 2009). Ligand-activated relaxed
TCR-CD3 might reduce contacts between TMRs of ab and zz,
making zz prone to detaching from the rest of the complex by
DDM during membrane extraction. As our data suggest, TMR
quaternary structure relaxation activated by pMHC (or anti-
CD3 Ab) or by TMR mutations promotes ITAM accessibility by
active-Lck (Nika et al., 2010), which would require conforma-
tional changes of membrane-tethered CD3 intracellular tails
(Xu et al., 2008). These are intrinsically disordered, and hence,
they may lack mechanical rigidity required to respond to TMR
movements. We suggest that subtle untying of TMRs may
reduce the grip of CD3 intracellular tails to the membrane and
favor ITAM tyrosine exposure (Figure S7K). Phosphatidylserine
(PS) (Xu et al., 2008) and PIP2 (Chouaki Benmansour et al.,
2018) appear to keep CD3 tails retracted onto the PM. A possi-
bility is that TMR octamer rearrangement permits fast exchange
of PIP2 and PSwith neutral lipids that may reduce CD3z and ε tail
interaction with the lipid bilayer (Figure S7K), augmenting ITAM
tyrosine exposure to active-Lck. Changes in cholesterol interact-
ing with TMR helices (Swamy et al., 2016;Wang et al., 2016) and/
or ITAM tyrosines might be part of this mechanism. Agonist anti-
CD3εmAbproduced a similar gain of function in TMRmutants, in
agreement with CD3ε ECD lying on a conformational trajectory
activated by pMHC.
We showed that binding of sm-pMHC to membrane-bound or
detergent-solubilized TCR-CD3 suffices to induce TCR-CD3
relaxation and signal transduction. Stimulation of TCR-CD3 by
sm-pMHC alone agrees with a genuine allosteric mechanism,
as hinted by our genetic perturbation analysis. Allosteric activa-
tion occurred without co-receptor or clustering or force, makingb-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b and z. The arrow indicates b2
representative pErk IB. Fourth panel, x ± SD of pErk, n = 3, unpaired t test p <
Right, x ± SD of pErk, n = 3, unpaired t test p < 0.05.
ed as in (A). First panel, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b and z.
st p < 0.05. Third panel, representative pErk IB. Fourth panel, x ± SEM of pErk,
anti-HA or Talon beads. Left, b-HA (lanes 1, 3) or His (lanes 2, 4) PD and IB for b
t p < 0.0001.
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chanosensing (Das et al., 2015; Kim et al., 2009; Liu et al.,
2014) dispensable for signal ignition. AKd of 7 mMcould not allow
to show quaternary structure relaxation of 9V-A2-bound versus
free 1G4 TCR. However, this was possible with 1G4 variants
wtc51 and QM-a capable of binding 9V-A2 with a Kd of 15 nM
and 140 nM, which is within the physiological Kd range for
pMHC agonists (Aleksic et al., 2012; Cole et al., 2007; Stone
et al., 2009). A third example was 868, a cytotoxic T lymphocyte
(CTL)-derived anti-HIV strong TCR pMHC binder. However, the
DSA may limit the conclusions that can be drawn about weaker
ligand interactions, and future work is required to address this
conclusively. Nonetheless, allosterically regulated signaling by
TCR-CD3 should be valid for the entire range of pMHC affinities,
as independent studies showed that allosteric changes in TCRab
occurred upon pMHC binding of Kd ranging between 5 and
0.04 mM (Beddoe et al., 2009; Natarajan et al., 2017; He et al.,
2020; Rangarajan et al., 2018).
Allosterically induced interactions propagate at distances of
nanometers in tens of ms to 1–2 ms (Kern and Zuiderweg,
2003; Natarajan et al., 2017; Rangarajan et al., 2018), which is
much faster than the fastest half-lives (z200 ms) of pMHC-
TCRab interactions (e.g., positively selecting pMHC; Hong
et al., 2018). Thus, it is conceivable that TCRab binding of very
weak or strong agonists can activate TCR-CD3 by allosteric
regulation. Allosterically regulated receptor tyrosine kinases
(RTKs) and G-protein coupled receptors (GPCRs) function with
allosteric modality when binding ligands of a wide difference in
affinity (Freed et al., 2017; Furness et al., 2016; Lane et al., 2017).
Early work did not detect a [Ca2+]i increase by the pMHC
monomer (Boniface et al., 1998), unless CD8 was co-engaged
(Delon et al., 1998). This apparent conflict with our data can be
reconciled by considering differences in sensitivity of the outputs
measured (i.e., [Ca2+]i versus pErk) and increased pMHC dwell-
time binding in our experiments. Moreover, membrane-tethered
pMHCs have considerably increased kon (and little or no change
in koff) compared to soluble pMHC (Huppa et al., 2010; O’Donog-
hue et al., 2013), indicating more effective entropically -driven
signaling by the former. Moreover, [Ca2+]i high amplitude and
duration require sustained TCRab engagement (Irvine et al.,
2002; Lewis, 2020) achieved by higher lateral ordering of
signaling complexes in micro-clusters at the immunological syn-
apse (Varma et al., 2006). Co-receptors and clustering allow
recording robust intracellular signaling required for full T cell acti-
vation, which may not be required for just igniting TCR-CD3
signal transduction as sm-pMHC alone does.
Reduced koff of the TCR-pMHC interaction is observed when
subjected to z10–20 pN pulling force, meaning ‘‘catch-bond’’
formation (Liu et al., 2014). However, mechanical force gener-
ated by membrane fluctuations and/or dedicated actin protru-
sions occur on a timescale of several seconds, which is two to
three orders of magnitude slower than allosteric changes.
Thus, pMHC-induced initial signal transduction may occur
without mechanical force. Interestingly, recent biophysical data
suggest that force developed between membrane-tethered
TCR-CD3 and pMHC is of low magnitude (z 2pN) (Göhring
et al., 2021). Perhaps, low-amplitude force may extend purely
allosterically induced interactions.Changes in conformational dynamics have long-range conse-
quences of functional relevance, amechanismknown as dynamic
allostery relyingonconformationalentropy (TzengandKalodimos,
2012). Conformational entropy cannot be frequently observed in
proteins’ crystalline state, as it is unlikely to capture a higher-en-
ergy (activated) state. However, NMR can correlate fast local
conformational changes (ps, ns) occurring at distant sites over
timescales of ms toms and distances of nm (Kern and Zuiderweg,
2003; Natarajan et al., 2017). Dynamic allostery may apply to
TCRab, as pMHC binding induces changes in conformational dy-
namics at distal H3, H4 helices, and FG loopofCb andCaAB loop
(Beddoe et al., 2009; He et al., 2020; Natarajan et al., 2017; Ran-
garajan et al., 2018), with the latter having been captured thus
far in only a single crystal structure (Kjer-Nielsen et al., 2003).
Our data should help reconcile controversies about the TCR-
CD3 signaling mechanism. Thus, pMHC co-engagement by
TCR and co-receptor is conditional on initial TCR-CD3 signaling
(Casas et al., 2014; Jiang et al., 2011), and catch-bonding ap-
pears to depend in part on TCR signaling (Hong et al., 2018).
We found evidence for enhanced basal signaling inducing clus-
tering that is erased by Lck inhibition. These data suggest that all
these events are instigated by an initial mechanism of allosteric
nature induced solely by pMHC binding. Thus, co-receptor
engagement, receptor clustering, shielding fromPTPs, and acto-
myosin-driven mechanical force may stabilize/potentiate initial
allosterically induced signaling by helping reduce physical and
chemical noise and augmenting/stabilizing signals of narrow
amplitude and duration initiated by sparse engagement of
pMHC (Brameshuber et al., 2018).
Binding of different CDR interfaces might activate different
conformational changes. If so, ligand potency may reflect com-
binations of binding kinetics and conformational trajectories.
Alternatively, different ligand-receptor pairs may induce similar
conformational trajectories. Future functional studies with
TCR-CD3 binding pMHC with non-noncanonical orientations
(Adams et al., 2011), MDSs, native nanodiscs, and genetic
perturbation should help clarify this question and provide further
insights on the mechanism that triggers TCR-CD3 signaling.
Limitations of the study
We have shown that signaling is activated by pMHC-induced
changes of TCR-CD3 quaternary structure. For this study, we
had to use TCRs of reduced koff for pMHC, as limitations of
DSA did not allow us to show the same effect for weak agonists.
However, structural studies have shown allosteric changes
occurring upon CaCb binding to medium-range agonists. More-
over, conformational change propagation occurs at two orders
of magnitude faster than the dwell-time of the weakest agonists,
such as that of self-pMHC. Although this finding supports our
conclusions, further work is required to formally demonstrate
their validity regardless of TCR affinity for pMHC.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLECell Reports 36, 109375, July 13, 2021 15
Article
ll
OPEN ACCESSd RESOURCE AVAILABILITY
B Lead contact
B Materials availability
B Data and code availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Cell lines
B Primary T cells
d METHOD DETAILS
B DNA constructs and cloning
B CRISPR/Cas9-mediated z knock-out
B TCR-CD3 expression
B Preparation of pMHC monomers and tetramers
B Preparation of UCHT1-Fab’ fragment
B Flow cytometry
B Mathematical modeling
B Biochemical analysis of the TCR-CD3 complex
B Ligand-induced TCR-CD3 quaternary structure
changes
B Microscopy
B Atomistic Molecular Dynamics Simulations
B Modeling of the 1G4 TCR affinity mutants
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Flow cytometry






Supplemental information can be found online at https://doi.org/10.1016/j.
celrep.2021.109375.
ACKNOWLEDGMENTS
We acknowledge the following: grant WT200844/Z/16/Z to O.A.,
WT092970MA and WT208361/Z/17/Z to M.S.P.S., WT100262Z/12/Z to
M.L.D., WT207537/Z/17/Z to O.D., WTSBF002\1031, Springboard Award
from the Academy of Medical Sciences (GB) to A.C.K, ERC-2014-AdG
670930 to S.B., Care-for-Rare Postgraduate Fellowship to A.-L.L., and
High-Performance Computing facilities, University of Leeds. We thank Ju-
liane Cohen, Christine Ralf, and Salvatore Valvo for technical support;
John Orban, Brian Baker, Ian Wilson, Gerhard Sch€utz, Pedro Carvalho,
Marco Fritzsche, Hai-Tao He, Immanuel Luescher, Cheng Zhu, and Andrew
Sewell for discussions, suggestions, and reading the manuscript; and C.R.
and J.C. and Ana Maria Vallés for manuscript editing. We apologize to col-
leagues whose work could not be adequately cited here because of space
limitation.
AUTHOR CONTRIBUTIONS
Conceptualization, O.A.; methodology, A.-L.L., G.M., N.P., A.C., D.C., R.R.,
D.K.C., M.L., S.B., A.C.K., D.P., O.D., M.L.D., M.S.P.S., and O.A.; software,
A.C.K. and O.D.; formal data analysis, A.-L.L., G.M., N.P., A.C., D.C., D.P.,
S.B., O.D., M.S.P.S., and O.A.; investigation, A.-L.L., G.M., N.P., A.C., D.C.,
A.C.K., S.B., D.G., D.K.C., D.P., M.S.P.S., and O.A.; resources, S.B.; writing
– original draft, O.A.; writing – review and editing, O.A., A.-L.L., G.M., N.P.,
A.C., D.P., A.C.K., M.S.P.S., D.K.C., M.L., M.L.D., and D.C.; visualization,
G.M., A.-L.L., N.P., A.C.K., A.C., D.C., D.P., D.K.C., S.B., and O.A.; supervi-
sion, A.C.K., M.S.P.S., M.L.D., and O.A.; funding acquisition, A.C.K.,
M.S.P.S., M.L.D., and O.A.16 Cell Reports 36, 109375, July 13, 2021DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: October 7, 2020
Revised: May 5, 2021
Accepted: June 18, 2021
Published: July 13, 2021
REFERENCES
Acuto, O., Di Bartolo, V., andMichel, F. (2008). Tailoring T-cell receptor signals
by proximal negative feedback mechanisms. Nat. Rev. Immunol. 8, 699–712.
Adams, J.J., Narayanan, S., Liu, B., Birnbaum, M.E., Kruse, A.C., Bowerman,
N.A., Chen, W., Levin, A.M., Connolly, J.M., Zhu, C., et al. (2011). T cell recep-
tor signaling is limited by docking geometry to peptide-major histocompatibil-
ity complex. Immunity 35, 681–693.
Alcover, A., Mariuzza, R.A., Ermonval, M., and Acuto, O. (1990). Lysine 271 in
the transmembrane domain of the T-cell antigen receptor beta chain is neces-
sary for its assembly with the CD3 complex but not for alpha/beta dimerization.
J. Biol. Chem. 265, 4131–4135.
Alcover, A., Alarcón, B., and Di Bartolo, V. (2018). Cell Biology of T Cell Recep-
tor Expression and Regulation. Annu. Rev. Immunol. 36, 103–125.
Aleksic, M., Dushek, O., Zhang, H., Shenderov, E., Chen, J.L., Cerundolo, V.,
Coombs, D., and van der Merwe, P.A. (2010). Dependence of T cell antigen
recognition on T cell receptor-peptide MHC confinement time. Immunity 32,
163–174.
Aleksic, M., Liddy, N., Molloy, P.E., Pumphrey, N., Vuidepot, A., Chang, K.M.,
and Jakobsen, B.K. (2012). Different affinity windows for virus and cancer-spe-
cific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol.
42, 3174–3179.
Altman, J.D., and Davis, M.M. (2003). MHC-peptide tetramers to visualize an-
tigen-specific T cells. Curr. Protoc. Immunol. Chapter 17, Unit 17.3.
Baker, B.M., Scott, D.R., Blevins, S.J., and Hawse, W.F. (2012). Structural and
dynamic control of T-cell receptor specificity, cross-reactivity, and binding
mechanism. Immunol. Rev. 250, 10–31.
Bates, M., Huang, B., Dempsey, G.T., and Zhuang, X. (2007). Multicolor super-
resolution imaging with photo-switchable fluorescent probes. Science 317,
1749–1753.
Beddoe, T., Chen, Z., Clements, C.S., Ely, L.K., Bushell, S.R., Vivian, J.P., Kjer-
Nielsen, L., Pang, S.S., Dunstone, M.A., Liu, Y.C., et al. (2009). Antigen ligation
triggers a conformational change within the constant domain of the alphabeta
T cell receptor. Immunity 30, 777–788.
Boniface, J.J., Rabinowitz, J.D., W€ulfing, C., Hampl, J., Reich, Z., Altman, J.D.,
Kantor, R.M., Beeson, C., McConnell, H.M., and Davis, M.M. (1998). Initiation
of signal transduction through the T cell receptor requires the multivalent
engagement of peptide/MHC ligands [corrected]. Immunity 9, 459–466.
Brameshuber, M., Kellner, F., Rossboth, B.K., Ta, H., Alge, K., Sevcsik, E.,
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Antibodies
Mouse anti-human AF647 CD3z pY142 mAb BD Bioscience Cat # 558489; RRID:AB_647152
Mouse anti-human PE CD3z pY142 mAb BD Bioscience Cat# 558448, RRID:AB_647237
Mouse anti-human AF647 CD3ε mAb BioLegend Cat# 300422, RRID:AB_493092
Mouse anti-human BV421 CD3ε mAb BioLegend Cat# 300434, RRID:AB_10962690
Mouse anti-human PE CD3ε mAb BioLegend Cat# 300456, RRID:AB_2564150
Mouse biotinylated anti-human CD3ε mAb BioLegend Cat# 300404, RRID:AB_314058
Rabbit anti-human AF647 pErk mAb Cell Signaling Technology Cat# 4375, RRID:AB_10706777
Rabbit anti-pTyr416 Src polyclonal Ab Cell Signaling Technology Cat# 2101, RRID:AB_331697
Rabbit anti-human ERK 1/2 polyclonal Ab Cell Signaling Technology Cat# 9107, RRID:AB_10695739
Rabbit anti-HA mAb Cell Signaling Technology Cat# 3724, RRID:AB_1549585
Rabbit anti-human CD3 g mAb Abcam Cat # 134096
Rabbit anti-human CD3 d polyclonal Ab GeneTex Cat# GTX105811, RRID:AB_11166991
Mouse AF488 anti-HA mAb Cell Signaling Technology Cat# 2350, RRID:AB_491023
Mouse AF647 anti-HA mAb Cell Signaling Technology Cat# 3444, RRID:AB_10693329
Rat anti-human CD3ε mAb Cell Signaling Technology Cat# 4443, RRID:AB_560945
Mouse anti-CD3z mAb Santa Cruz Biotechnology Cat# sc-1239, RRID:AB_627020
Rabbit anti-CD3z pY142 mAb Abcam Cat# ab68235, RRID:AB_11156649
Mouse anti-Actin mAb Merck Millipore Cat# MAB1501, RRID:AB_2223041
Mouse anti-pTyr mAb Merck Millipore Cat# 05-321, RRID:AB_309678
Mouse anti-human CD3ε mAb BioXCell Cat# BE0231, RRID:AB_2687713
Mouse anti-HLA-A, B, C mAb BioLegend Cat# 311423, RRID:AB_1877080
Mouse anti-human APC HLA-A2 mAb BioLegend Cat# 343308, RRID:AB_2561567
Rabbit anti-CD3z polyclonal Ab San José et al., 1998 N/A
Bacterial and virus strains
E.coli DH5a Competent Cells Thermo Fisher Cat # 18265-017
E.coli Stbl3 Competent Cells Invitrogen Cat # C7373-03
Chemicals, peptides, and recombinant proteins
10X Tris/Glycine/SDS Biorad Cat # 161-0772
16% Formaldehyde (w/v), Methanol-free Thermo Fisher Cat # 28908
2-Mercaptoethylamine-HCl Thermo Fisher Cat # 20408
Annexin-V-AF647 BioLegend Cat # 640912
Annexin-V-PE BioLegend Cat # 640908
Alexa Fluor 488 C5 Maleimide Thermo Fisher Cat # A10254
Alexa Fluor 647 C2 Maleimide Thermo Fisher Cat # A20347
Amicon Ultra 15 mL centrifugal filter units Millipore Cat # UFC901008
Anti-HA-conjugated agarose beads Sigma Aldrich Cat # AL2095
A770041 Lck inhibitor Axon Medchem Cat # 1698
BamH1 New England Biolabs Cat # R0136
BD Cytofix buffer BD Biosciences Cat # 554655
BD PhosFlow Perm/Wash buffer 1 BD Biosciences Cat # 55785
Benzonase Nuclease Millipore Cat # 71206-25KUN
BirA kit Avidity Cat # BirA500
Bovine serum albumin (BSA) Sigma Aldrich Cat # A4503-100G
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Bug Buster protein extraction reagent Millipore Cat # 70584-4
Catalase Sigma Aldrich Cat # C100
CellTraceTM Violet Thermo Fisher Cat # C34557
Centricon Plus-70 centrifugal filter units Millipore Cat # UFC703008
Cysteamine MEA Sigma Aldrich Cat # 30070
Disposable PD 10 desalting column G&E Healthcare Cat # 17-0851-01
DMEM Sigma Aldrich Cat # D6429
DMSO Sigma Aldrich Cat # D8418-100ML
Doxycycline hyclade Sigma Aldrich Cat # D9891-10G
DpnI New England Biolabs Cat # R0176
EasySep Human CD8 T cell isolation kit STEMCELL Cat # 17953
EcoR1 New England Biolabs Cat # R0101
Endoglycosidase H (endo H) New England Biolabs Cat # P0702S
EZ-Link Maleimide-PEG2 biotin Thermo Fisher Cat # 21901BID
Fetal bovine serum (FBS) GIBCO Cat # 10500-064
Glucose Sigma Aldrich Cat # G8270
Glucose Oxidase Sigma Aldrich Cat # G2133
Glutamine GIBCO Cat # A2916801
HA peptide Sigma Aldrich Cat # I2149
His-Pur Cobalt Resin Thermo Fisher Cat # 89964
His-Streptavidin (AA 25-183) protein (His tag) Antibodies Online Cat # ABIN666648
HLA-A2-SLYNTIATL (6I-A2) monomer Cole et al., 2017 N/A
Human T-activator CD3/CD28 Dynabeads Thermo Fisher Scientific Cat # 11161D
Human serum Sigma Aldrich Cat # H4522
ICAM-1 protein, recombinant human R&D Systems Cat # 720-IC-050
Imidazole Sigma Aldrich Cat # I202-500G
Iodoacetamide Sigma Aldrich Cat # I6125
Ionomycin Sigma Aldrich Cat # I0634
Lysonase (Lysozyme + Benzonase) Millipore Cat # 71230-3
MART-1 peptide (> 95% purity by HPLC) Cambridge Peptides Inc. N/A
n-Dodecyl b-D-maltoside (DDM) Millipore Cat # 324355-5GM
Non-essential amino acids solution GIBCO Cat # 11140050
Not 1 New England Biolabs Cat # R0189
NuPAGE LDS Sample Buffer Invitrogen Cat # NP0007
NuPAGE Sample Reducing Agent Invitrogen Cat # NP009
NY-ESO-1 peptides (> 95% purity by HPLC) Cambridge Peptides Inc. N/A
PEG-itTM SBI Cat # LV810A-1
PEIpro Polyplus Cat # 115-010
Pepsin Thermo Fisher Cat # 20343
Phosphate Buffer Saline (PBS) Sigma Aldrich Cat # P4417
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich Cat # P1585
Phycoerythrin-conjugated streptavidin Sigma Aldrich Cat # S4762-5MG
Pme1 New England Biolabs Cat # R0560
Polybrene Sigma Aldrich Cat # 28728554
Proteases inhibitors (cOmplete, EDTA free) Roche Cat # 11873580001
Protein G agarose Thermo Fisher Cat # 15920
Puromycin GIBCO Cat # A11138-03
RPMI 1640 Sigma Aldrich Cat # R8758
Sodium Acetate Thermo Fisher Cat # 10000500
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Sodium Fluoride Sigma Aldrich Cat # S1504-500G
Sodium Orthovanadate New England Biolabs Cat # 11873580001
Sodium Pyruvate GIBCO Cat # 11360070
Strep-Tactin Sepharose 50% suspension IBA Lifesciences Cat # 2-1201-010
Streptavidin Sepharose High Performance beads GE Healthcare Cat # 17-5113-01
Tetracycline-free FBS Clontech Cat # 631106
Trans-Blot Turbo Midi Nitrocellulose Transfer Packs Biorad Cat # 170-4159
Trans-Blot Turbo Mini Nitrocellulose Transfer Packs Biorad Cat # 170-4158
Trizma base Sigma Cat # T6066
Xba1 New England Biolabs Cat # R0145
Zeba Spin Desalting Thermo Fisher Cat # 89889
0.45 mm sterile filters Sartorius Stedim Cat # 1655-K
8 well chamber Glass m-slide Ibidi Cat # 80821
96-well V-bottom plates Thermo Fisher Cat # 634-0009
Critical commercial assays
QIAprep Spin Midiprep Kit QIAGEN Cat # 27106
QIAprep Spin Miniprep Kit QIAGEN Cat # 12243
BP Clonase II kit Thermo Fisher Cat # 11791020
LR Clonase II kit Thermo Fisher Cat # 11789020
Experimental models: Cell lines
Human: TCRb CD8+ Jurkat 31.13; (J13.31) Alcover et al., 1990 N/A
Human: TCRab/CD8 Jurkat J76;
(CD8 J76)
Heemskerk et al., 2003 N/A
Human: TCRab/CD8+ Jurkat J76;(J76) This study N/A
Human: 1G4aWTbWT J76 CD8;(CD8 J76 1G4 WT) This study N/A
Human: 1G4aWTbWT J76 CD8+;(J76
1G4 WT)
This study N/A
Human: 1G4aWTbA291 J76 CD8; (CD8
J76 1G4 bA291)
This study N/A
Human: 1G4aWTbA291 J76 CD8+; (J76
1G4 bA291)
This study N/A
Human: 1G4aWTbF291 J76 CD8; (CD8
J76 1G4 bF291)
This study N/A
Human: 1G4aWTbL291 J76 CD8; (CD8
J76 1G4 bL291)
This study N/A
Human: 1G4aWTbA293 J76 CD8; (CD8
J76 1G4 bA293)
This study N/A
Human: 1G4aWTbA303 J76 CD8; (CD8
J76 1G4 bA303)
This study N/A
Human: 2H5aWTbWT J76 CD8;(J76 CD8 2H5 WT) This study N/A
Human: 2H5aWTbA291 J76 CD8;(J76 CD8 2H5 bA291) This study N/A
Human: 1G4aWTbWT CD3z/ J76 CD8+; (J76-1G4WT-zKO) This study N/A
Human: 1G4 aWTbWT CD3z/ J76 CD8+ expressing
CD3zWT; (J76-1G4WT-zKO expressing zWT)
This study N/A
Human: 1G4 aWTbWT CD3z/ J76 CD8+ expressing
zI38A; (J76-1G4WT-zKO expressing zI38A)
This study N/A
Human: 1G4 aWTbWT CD3-z/ J76 CD8+ expressing
zI41A; (J76-1G4WT-zKO expressing zI41A)
This study N/A
Human: 1G4 wtc51 J76 CD8+; (J76 wtc51) This study N/A
Human: 1G4 wtc51 J76 CD8; (CD8 J76 wtc51) This study N/A
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Human: 1G4 QM-a J76 CD8+; (QM-a) This study N/A
Human: 868 J76 CD8+; (J76 868) This study N/A
Human: 868 J76 CD8; (CD8 J76 868) This study N/A
Human CD8+ primary T cell 1G4 wtc51 This study N/A
Human: 1G4 aWTbWT CD3z/ expressing
CD3z-TST (J76 1G4 z-TST)
This study N/A
Human: HEK293T ATCC Cat # CRL-3216
Human: Lenti-X293T Clontech Cat # 632180
Oligonucleotides
See Table S2 This study N/A
Recombinant DNA
pDONR-221 Thermo Fisher scientific Cat # 12536017
pEF3 FLAG K. Nika, University of Oxford N/A
pEF3 HA K. Nika, University of Oxford N/A
pEXPR-IBA103 IBA Lifesciences Cat # 2-3503-000
pHR-CD8aa A. Van Der Merwe, University
of Oxford
N/A
pHR-SIN-BX-IRES-Emerald V. Cerundolo, University
of Oxford
N/A
pLIX-402 Addgene Cat # 41394
pLEX_307 Addgene Cat # 41392
psPAX2 Addgene Cat # 12260
pVSV-G Addgene Cat # 14888
Software and algorithms
Flow Jo BD N/A
GROMACS http://www.gromacs.org/ N/A
Image Studio Li-COR Bioscience N/A
Insight3 B. Huang, University of
California, San Francisco
N/A
Jalview Waterhouse et al., 2009 N/A
MATLAB software S. Shelby and S. Veatch,
University of Michigan
N/A
OriginPro 2017 OriginLab N/A
Prism GraphPad Software N/A
PyMOL Schrödinger LLC N/A
SnapGene GSL Biotech LLC N/A
Other
Hi-Load 16/600 Superdex 200 pg Column GE Healthcare Cat # 28-9893-35





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Oreste
Acuto (oreste.acuto@path.ox.ac.uk).
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resources table.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Cell lines were maintained at 37C with 5% CO2 in a humidified incubator (Heraeus). Human embryonic kidney epithelial 293T cells
HEK293T (ATCC CRL-3216) and Lenti-X293T (Clontech) cell lines were cultured in complete DMEM (Sigma Aldrich) supplemented
with 15% fetal bovine serum (FBS). Jurkat-derived cell line variants 31.13 (Alcover et al., 1990) (abbreviated J31.13) and J76 (Heem-
skerk et al., 2003), which lack expression of TCRb and TCRab respectively, were cultured in RPMI 1640 supplemented with 10%
FBS. Key resources table lists all the above cell lines and those that were derived from J31.13 and J76 in this study. Cells were
routinely tested and found negative for mycoplasma and are not STR profiled. Jurkat cell lines containing a tetracycline-inducible
gene expression systems were maintained in RPMI 1640 supplemented with 10% tetracycline-negative FBS (Clontech).
Primary T cells
Primary CD8 T cells were obtained from HLA-A2 healthy donor blood cones (NHS) by density gradient centrifugation and negative
selection using EasySep Human CD8 T cell isolation kit (STEMCELL). Isolated T cells were rested overnight at 2 3 106/ml in RPMI
medium (Sigma) supplemented with 2 mM Glutamine, 1 mM Sodium Pyruvate, Non-essential AA, 50 mg/ml Kanamycin, 5% human
serum (Sigma).
METHOD DETAILS
DNA constructs and cloning
All plasmid DNA was propagated in E. coli strains DH5a or Stbl3.
Generation of 1G4 a and 1G4 b plasmids for transient transfections
1G4 a and b sequences were amplified from total cDNA extracted (Roche cDNA extraction kit) from an established 1G4 expressing
Jurkat cell line (Aleksic et al., 2010) with appropriate primers (see primers in Table S2) and cloned into pEF3 with a Flag- and HA-tag
respectively.
Site directed mutagenesis
Single amino acidmutations in the 1G4 b chain were introduced using amodifiedQuikChange protocol (Agilent). Briefly, PCR primers
were generated using theQuikChange open source software. PCRwas carried out with an optimized protocol and the resulting prod-
uct was purified using QiaQuick Gel purification kit (QIAGEN). A fraction of purified PCR was digested with DpnI for 2 h and used to
transform Stbl3 E. coli (Invitrogen). DNA was extracted from colonies, analyzed by gel electrophoresis and sequenced (Source
BioScience. UK).
Generation of the self-cleavable 1G4 ab construct (stable cell lines)
A DNA construct was designed to obtain a single mRNA for b and a giving rise to a single polypeptide separated by the foot-and-
mouth disease virus 2A (F2A) self-cleavable sequence (Ryan et al., 1991). This strategy should facilitate expression of similar amounts
of b and a proteins. The aa sequence of the entire construct is provided in Table S1. See Figure S1A for a schematic of the construct.
Constructs for Tet-inducible expression of 1G4 ab, 2H5 ab, zWTandmutants, affinity enhanced 1G4 (wtc51 andQM-a),
zTST and constitutive 1G4 ab and 868 TCR
To generate an inducible expression system for 1G4 abWT and 1G4 aWT/bA291, the sequence coding for the self- cleavable single
polypeptide b-HA-F2A-a-FLAG was cloned into the doxycycline inducible Gateway cloning plasmid pLIX-402 (Addgene) following
the manufacturer’s guidelines for Gateway cloning. Briefly, the DNA sequence containing the entire ab sequence was PCR amplified
from the constitutive expression plasmid pHR with primers containing the Gateway recombination sites (see primers for Gateway
cloning in Table S2). Purified PCR products were inserted via the BP recombination reaction into the Gateway entry vector
pDONR-221 (Thermo Fisher). After verification of successful recombination by automated sequencing (Source Bioscience, UK),
the resulting entry clones were used for a LR recombination reaction to insert the sequence into the pLIX-402 destination vector
(Addgene), which carries a tetracycline-inducible promoter for conditional expression of the gene of interest. Both BP and LR reac-
tions were performed with BP and LRClonase II kits (Thermo Fisher). To clone the high affinity TCRs (wtc51 and QM-a) and the entire
panel of 1G4 and 2H5 b and zmutants, synthetic DNA fragments coding for either self-cleavable single polypeptide 1G4 ab (aWTplus
bWT or mutants bA291, bL291, bF291) or 2H5WT and 2H5 bA291 or zWT andmutants zA38 and zA41 were purchased fromGeneArt
Gene Synthesis (Thermo Fisher). All DNA fragments contained consensus sequences for Gateway Cloning System and the ab and z
constructs were introduced into the Gateway plasmid pLIX-402 for inducible expression, following the Gateway cloning protocol as
described above. After cloning into the expression vectors, the coding sequences were verified by automated sequencing (Source
BioScience, UK). To generate a twin-strep tagged (TST) z containing cell-line the sequence of z was cloned, after XbaI/EcoRI diges-
tion, into the plasmid pEXP103 IBA (IBA Lifesciences), to be fused with a TS-tag at the C terminus. The zTST sequence was subse-
quently amplified and cloned into pLIX-402 destination vector following the gateway procedure as described above. (See primers fore5 Cell Reports 36, 109375, July 13, 2021
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OPEN ACCESSGateway cloning in Table S2). To generate a constitutive expression system for 1G4 ab and 868 ab synthetic DNA fragments coding
for either self- cleavable single polypeptide 1G4 ab and 868 ab were purchased from GeneArt Gene Synthesis and were introduced
into the Gateway plasmid pLEX 307 (Addgene) for constitutive expression, following the Gateway cloning protocol as described
above.
CRISPR/Cas9-mediated z knock-out
CRISPR/Cas9 mediated knock-out (KO) of z was achieved using the pX458 two component vector (Addgene) and the guide
sequence CAGGCACAGTTGCCGATTACAGG. J76 expressing CD8 and the single polypeptide 1G4 ab were transiently transfected
and CD3 negative cells were sorted. Efficient knock-out was verified by transient transfection of the proteins of interest and analysis
of rescue by FACS analysis.
TCR-CD3 expression
Transient expression of TCR-CD3
J31.13 cells were grown to approximately 0.5 – 0.6 3 106/ml, cells were counted, harvested (2 3 106 cells per electroporation) and
centrifuged at 1,200 rpm. The supernatant (conditioned medium) was collected, diluted with equal volume of RPMI containing 10%
FBS and kept at 37C in the incubator. Cells were washed twice in RPMI and re-suspended in 400 mL RPMI and placed in sterile
Biorad Genepulser Cuvettes (0.4 cm) containing 2 mg of plasmid DNA per 106 cells. Constructs and mutant DNA were routinely pu-
rified from E. coli using QIAGENmini- or midi-prep kits (QIAGEN). Electroporation was performed with a Biorad GenePulser X-cell at
260 V, 1 pulse of 25 ms using the square root method. Cells were flushed out of the cuvette with 200 mL conditioned medium and
placed at 37C in the incubator until final use. Cells were usually assayed after 24 - 48 h and analyzed by flow cytometry for CD3
surface expression or for pErk in response to pMHC tetramer.
Generation of stable cell lines
For lentivirus infection, recipient cells were cultured up to approximately 0.5 – 0.6 3 106/ml. Cells were washed once in RPMI,
checked for viability, counted and adjusted to 106/ml in RPMI supplemented with 10% FBS (tetracycline-free (Tet-) in the case of
transduction with doxycycline-inducible plasmids) (GIBCO or Clontech) and 5 mg/ml of polybrene (Sigma). Cells were plated in
12-well (1 ml/well) or 6-wells plates (2 ml/well) and one aliquot of lentivirus was added (for preparation of lentiviruses see below).
24 h post-infection, cells were washed and re-suspended in RPMI 10%FBS (standard or Tet-). After transduction with a plasmid con-
taining an antibiotic selection marker, cells were cultured for an additional 24 h before starting selection with puromycin (1 mg/ml,
GIBCO). With adequate lentivirus concentration, cell mortality was relatively low.
For tetracycline-inducible cell lines, gene expression could be started after 72 h by adding 0.1 - 1 mg/ml of doxycycline hyclate
(Sigma Aldrich). Cells were collected after approximately 16 h and tested for CD3 expression and signaling by flow cytometry.
Primary T cells were plated in 24-well (1 ml/well) at 1 3 106/ml and stimulated with human T-activator CD3/CD28 Dynabeads
(Thermo Fisher Scientific) at 2:1 bead to T cell ratio in complete medium supplemented with 500 U/ml IL-2. After 48 h most of the
medium was removed and replaced with fresh medium supplemented with 500 U/ml IL-2, containing 40 mL of concentrated lentiviral
stock in presence of 5 mg/ml polybrene (Sigma). After 4 days the dynabeads were removed and 1G4 wtc51 positive cells were sorted
after (9V-A2)4-PE staining. Sorted cells were kept in complete medium supplemented with 500 U/ml IL-2 and re-stimulated with hu-
man T-activator CD3/CD28 Dynabeads 12 days after the sorting.
Production of lentiviral particles
Lentiviruses were generated using the packaging cell lines HEK293T or Lenti-X293T. The culture mediumwas exchanged with RPMI
with 10% FBS just prior to transfection. HEK293T or Lenti-X293T at 80% confluence were transfected using PEIpro (Polyplus) ac-
cording to the manufacturer’s instructions or by a standard calcium-phosphate precipitation protocol. The packaging plasmids
pVSVG and pSPAX2 were mixed with the lentivirus expression vectors containing the gene of interest. For the PEIpro transfection,
PEIpro solution was added to the plasmidsmix and immediately vortexed, left 15min at room temperature (RT) and then added drop-
wise to the cells by gently swirling the plate. For calcium-phosphate precipitation, cells were left 3 h with DNA-calcium-phosphate
precipitate and the media replaced with complete DMEM with 15% FBS. Independently of the transfection protocol, supernatant
containing lentiviral particles was collected after 48 h and filtered through a 0.45 mm sterile filter (Sartorius Stedim). Lentivirus
supernatants were either used immediately or concentrated with PEG-itTM (SBI) concentration kit according to the manufacturer’s
instruction. Briefly, lentiviral supernatants were mixed with Virus Precipitation Solution (SBI) to a final concentration of 1X Virus Pre-
cipitation Solution and incubated overnight at 4C followed by a centrifugation at 1,500 x g for 30 min at 4C. The pellet containing
lentivirus particles was re-suspended in 1/100 of the volume of the original cell culture using cold RPMI. Aliquots were immediately
frozen in cryogenic vials at - 80C and stored until use. Aliquots of each lentivirus batch were routinely pre-tested by serial dilution
titration. Frozen aliquots were thawed only once and used immediately with minimal loss of virus titer as determined by flow
cytometry.
Preparation of pMHC monomers and tetramers
pMHCmonomers were produced as described elsewhere (Altman and Davis, 2003) with some modifications. Human beta-2 micro-
globulin (b2 m) and the 1 - 278 segment of HLA-A*02:01 heavy chain with the AviTag at the C terminus were separately expressed in
E. coli. Both proteins were recovered from inclusion bodies with Bug Buster protein extraction reagent (Millipore) supplemented withCell Reports 36, 109375, July 13, 2021 e6
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400 mM L-arginine hydrochloride, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidised glutathione, 0.1 mM PMSF) supple-
mented with 0.5 mM urea and 10 mg/ml synthetic peptide (> 95% purity by HPLC) of either one the following variants of the NY-
ESO-1 antigen (Aleksic et al., 2010) (SLLMWITQC, residues 157-165): 9V (SLLMWITQV, Kd 7.2 ± 0.5 mM), 6V (SLLMWVTQV, Kd
18 mM) or the MART-1 tumor antigen (MART-1 26-35 (ELAGIGILTV) (Circosta et al., 2009) or the 6I (SLYNTIATL, Cambridge Peptides
Inc.). The resulting soluble-monovalent-monodisperse pMHC (sm-pMHC) were indicated as: 9V-A2, 6V-A2, MART-1-A2 and 6I-A2.
Peptides were synthesized by standard solid-phase chemistry using F-moc for transient N-terminal protection. All peptides were
approximately 98% pure as determined by analytical HPLC and mass spectrometry. Lyophilized peptides were dissolved in DMSO
(Sigma) to 10 mg/ml and aliquoted of 100 mL in low-bind Eppendorf tubes and used immediately or stored at - 80C. The refold
mixture was stirred gently for 40 h at 4C, concentrated approximately 40-fold to 2.5 mL by centrifugation at 4C at 3,500 x g in Cen-
tricone Plus-70 centrifugal filter units (30 kD cut-off) (Merck Millipore) and desalted on a disposable PD 10 column (GE Healthcare)
by gravity flow eluting in 3.5 mL TBS. The eluent was subject to mono-biotinylation using a BirA kit (Avidity) and fractionated by FPLC
using a HiLoadTM 16/600 Superdex 200 pg column (GE Lifesciences) and the ÄKTA Pure (GE Healthcare) system. Fractions contain-
ing rHLA-A*02:01-b2 m dimers were pooled and concentrated in Amicon Ultra 15 mL centrifugal filter units (10 kD cut-off) (Merck
Millipore). After addition of glycerol to a final concentration of 5%, protein concentration was adjusted to 1 mg/ml measuring
OD280 and aliquots were frozen at - 80
C until use. We rigorously controlled the quality of monomers prior to performing experiments
by size-exclusion chromatography (SEC) and we also used multi-angle light scattering with size-exclusion chromatography (SEC-
MALS) for sm-9V-A2 to further control for mono-dispersity and unique molecular mass in the peak.
Tetramers were generated by slowly mixing aliquots of biotinylated rHLA-A*02:01-rb2mwith phycoerythrin (PE)-conjugated strep-
tavidin (Sigma) at RT under constant agitation as described earlier (Altman and Davis, 2003). Alternatively, His-streptavidin (Anti-
bodies Online) was used. The resulting tetramers, (9V-A2)4, (6V-A2)4, (MART-1-A2)4 and (6I-A2)4, were stored at 4
C until final use.
Preparation of UCHT1-Fab’ fragment
A Fab’ fragment was prepared from the purified mAb UCHT1 (BioXCell). Briefly, UCHT1 was digested with Pepsin (Thermo Fisher) in
100 mM Sodium Acetate (Thermo Fisher) for 24 h at 37C on a rocking platform. The digest was incubated overnight at 4C on a
rotating shaker with Protein G agarose (Thermo Fisher) to remove the Fc fragment. The resulting Fab2 was reduced with 2-Mercap-
toethylamine-HCl (MEA-HCl) (Thermo Fisher) for 90min at 37C, according to themanufacturer’s instructions, to obtain the Fab’ frag-
ment.MEA-HCl excesswas removed using a Zeba Spin Desalting column (Thermo Fisher) and the Fab’ fragment eluted in Phosphate
Buffered Saline (PBS, Sigma) at pH 7.0. The UCHT1-Fab’ was conjugated to biotin using EZ-Link Maleimide-PEG2 biotin (Thermo
Fisher) or to Alexa Fluor 647 or 488 using Alexa Fluor 647 C2 Maleimide and Alexa Fluor 488 C5 Maleimide respectively (Thermo
Fisher). The Fab’ was mixed in 1:10 molar ratio with 2 mM EZ-Link Maleimide-PEG2 biotin or with Alexa Fluor 647 C2 Maleimide
for 5 hwith slight agitation on a rocking platform at RT. Reagent excess was removed using a Zeba Spin Desalting column. The biotin,
Alexa Fluor 488 or Alexa Fluor 647-labeled UCHT1-Fab’ fragments were analyzed on a non-reduced 4 - 15%Mini-PROTEAN Precast
protein gel (Bio-Rad) and stored in PBS at 4C. The biotin-labeled UCHT1-Fab’ was further analyzed by FPLC to detect formation of
Fab’ aggregates. Biotin-labeled UCHT1-Fab’ was diluted to a concentration of 0.3 mg/ml in PBS and 40 ml were analyzed by size
exclusion chromatography. The analysis was carried out using a Superdex 200 increase 5/150 GL column (GE Lifesciences) and
the ÄKTA Pure system (GE Lifesciences). Fab’ was applied onto the column using a 40 ml loop at a flow rate of 100 ml/ml. Isocratic
elution with PBS occurred at 300 ml/min with a total elution volume of 3 ml.
Flow cytometry
General staining procedures
This section provides a description of the procedures used for antibody (Ab)-mediated cell staining for flow cytometry and data
acquisition. Staining was performed in 96-well V-bottom plates (Thermo Fisher) and centrifugations carried out at 670 x g for
1 min in a plate centrifuge (Eppendorf Centrifuge 5810R or Thermo IEC CL30 Centrifuge). Care was taken to gently re-suspend cells
after each centrifugation to avoid cell damage and/or death. To optimize the sensitivity of the flow cytometry-based assays, Abs used
in this study were systematically titrated for staining of cells expressing or lacking the target antigen and the conditions showing the
best signal-to-noise were chosen. Flow cytometry staining was routinely carried out in duplicates or triplicates. For cell surface
staining, 0.1 3 106 cells/sample were transferred into a 96-well V-bottom plate, washed once in 150 mL FACS buffer (0.5% bovine
serum albumin (BSA) (Sigma) in PBS). After spinning, supernatants were removed and cell pellets re-suspended in 50 mL staining
solution containing fluorescence-conjugated primary Ab (see Key resources table for a list of the Abs used in this study) diluted in
FACS buffer and incubated for 20 min at RT or for 30 min at 4C, depending on the Ab used. After removal of the staining solution,
samples were washed twice with 150 mL FACS buffer and flow cytometry data acquired immediately or cells were fixed with 150 mL
pre-warmed fixation solution (BD Cytofix, BD Biosciences) for 10 min at 37C. For staining of intracellular antigens, fixed samples
were washed twice in 150 mL permeabilisation buffer (BD Perm/Wash I, BD Biosciences), re-suspended in 150 mL permeabilisation
buffer and incubated at RT for 30 min. Permeabilised cells were stained in 50 mL permeabilisation buffer containing the desired Ab
dilution. For fluorescent-conjugated primary Ab staining, samples were incubated at RT for 1 h (except for anti-pY142 CD3z and anti-
HA, which were incubated at 4C for 2 h). When fluorescent-conjugated secondary Abs were used, they were diluted in 50 mL per-
meabilisation buffer and added to cells for 20 min at RT. After each staining, cells were washed 3 times with 150 mL permeabilisatione7 Cell Reports 36, 109375, July 13, 2021
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formed prior to fixation as described above. Samples were left in FACS buffer for storage and acquisition and acquired on a CyAn
ADP analyzer (Beckman Coulter) or BD LSR Fortessa X20 (BD Bioscience) as specified. Raw data was analyzed by FlowJo (FlowJo
Software part of BD). Counts, percentages or median intensity fluorescence values (MFI) were extracted from FlowJo as excel files.
Statistical analysis and non-linear regression were performed with Prism (GraphPad Software).
CellTrace violet labeling
Cells were washed once in PBS and adjusted to a final concentration of 106 cells/ml in pre-warmed PBS at 37C. CellTrace violet
(Thermo Fisher) or carrier control DMSO (Sigma) was added to reach the indicated staining concentration and cells were incubated
at 37C in the dark. After 20min, samples were diluted 5-fold in complete medium and incubated for an additional 5min at 37C in the
dark. After removal of the diluted staining solution, cells were re-suspended in complete medium, counted and cultured or mixed as
indicated.
UCHT1-Fab’ fragment binding
J76 1G4 WT or b mutants were induced for TCR expression with doxycycline 1 mg/ml for 96 h. TCR-deficient J76 CD8+ cells were
used to evaluate the background. Cells were harvested and stained with AF488-conjugated UCHT1-Fab’ at the indicated dilutions in
FACS buffer for 30 min at 4C. After removing excess of UCHT1-Fab’, cells were fixed, permeabilised and intracellular staining was
performed with Alexa647-conjugated anti-HA mAb (1:50) as described in the flow cytometry protocol section. Samples were ac-
quired on CyAn ADP analyzer (Beckman Coulter). Raw data was analyzed in FlowJo andMFI of UCHT1-Fab’ binding in the TCRb-HA
positive population extracted as excel files. Further analysis and statistical tests were performed in Prism (GraphPad Software). MFI
of UCHT1-Fab’ binding after background subtraction was plotted against the concentration of UCHT1-Fab’ and fitted with non-linear
regression (One site - Specific binding).
pMHC-tetramer binding to cells for association and dissociation analysis
To measure the relative association rate of pMHC tetramers to WT and bA291 TCR, J76 CD8+ 1G4 WT or bA291 cells were induced
for TCR expression with 1 mg/ml doxycycline for 48 - 72 h. TCR-deficient J76 cells were used to evaluate binding background. Cells
were labeled with 200 nM CellTrace violet (Thermo Fisher) or with carrier control DMSO (Sigma), mixed 1:1 and washed once before
being re-suspended at 203 106/ml in RPMI, pre-warmed at 37C. Cells were then distributed at 0.53 106 cells, 25 ml/well in a 96-well
V-bottom plate (Eppendorf) and equilibrated at 37C for 10 min in a ThermoMixer C (Eppendorf). 1:2 dilution series of 2X (6V-A2)4-PE
were added directly to the wells to a final concentration of 400 to 3.125 nM as indicated in the plot. After 10 min binding, a 3-fold
excess of fixation buffer (BD Cytofix) was added and samples fixed for 10 min at 37C. Samples were permeabilised and stained
intracellularly with anti-HA (1:50) to detect total TCRb as described in Flow cytometry protocols. To measure the relative dissociation
rate of pMHC tetramers from WT and bA291 TCR, the same procedure as for on-rate measurements was used. This included cells,
CellTrace violet labeling procedure, binding conditions and staining procedure, except that the assay was performed in 1.5 mL Ep-
pendorf tubes. The concentration of (6V-A2)4-PE in this assay was 50 nM. After 10min of pMHC tetramer binding to the cells at 37
C,
samples were washed once in RPMI containing 10% FBS and re-suspended at 106/ml in RPMI containing 10% FBS supplemented
with 10 mg/ml anti-HLA-A, B, C (BioLegend) to prevent rebinding of dissociated pMHC tetramer. Samples (0.2 3 106 cells in 200 ml)
were taken at the indicated times, washed once in FACS buffer and fixed for 2 h at 4C in fixation buffer (BD Cytofix). Cells were per-
meabilised and stained for TCRb-HA as for the binding assay. Samples were acquired on a CyAn ADP. Raw FACS data was analyzed
in FlowJo (FlowJo Software) and MFI of (6V-A2)4-PE binding and TCRb-HA were extracted as excel files. Further analysis and sta-
tistical tests were performed in Prism (GraphPad Software). The MFI of the (6V-A2)4-PE binding was corrected for background,
normalized for maximal binding (max. binding = 100%), plotted against the concentration of (6V-A2)4-PE or against the time after
initial binding and the curves were fitted by non-linear regression (Specific binding with Hill slope or Dissociation - One phase expo-
nential decay).
TCR-CD3 expression efficiency
To evaluate the efficiency of TCR-CD3 surface expression, J76 CD8- 1G4 (or 2H5)WT or bmutant cells were induced for TCR expres-
sion with 1 mg/ml doxycycline overnight at 0.3 3 106 cells/ml. Cells were incubated with 50 nM CellTrace violet or carrier control
DMSO (Sigma), mixed in a 1:1 ratio and stained for surface CD3 and intracellular TCRb-HA, using UCHT1 AF647-conjugated Fab’
and AF488-conjugated anti-HA mAb respectively, as described in Flow cytometry procedures. J76 CD8- 1G4 (or 2H5) WT or b mu-
tants, non-induced with doxycycline were used to evaluate binding background. Cells were analyzed on a BD LSR Fortessa X20 flow
cytometer (BD Biosciences) and acquired data was analyzed with FlowJo FACS analysis software V10.0 (Tree Star, BD). 2D plots of
TCRb-HA versus CD3were obtained and gates for different levels of TCRb-HA (low, medium and high) were applied. TheMFI ± SD of
CD3 and TCRb-HA was extracted within each gate and normalized to the WT in the corresponding gate. Statistical analysis using
unpaired t test was performed using Prism (GraphPad Software). MFI ± SD of TCRb-HA for 1G4 WT and b mutants in those bins
was not statistically significant (ns). The same procedure was used to evaluate the efficiency of TCR-CD3 surface expression in
J76 CD8+ 1G4 zKO expressing zWT and z mutants (zA38, zA41).
pMHC-tetramer stimulation for pErk or pz-dose-response
To measure proximal signaling in response to stimulation with pMHC, J76 CD8+ or CD8- 1G4 (or 2H5) WT or mutant cells were
induced for TCR expression with doxycycline (dox) overnight at 0.3 3 106 cells/ml. In all pMHC-tetramer stimulations for pErk,
J76 CD8+ or CD8- 1G4 WT (or 2H5 WT) were induced for TCR expression with 0.8 - 0.2 mg/ml of dox whereas b (or z) mutants
were induced with 1 mg/ml. Different doses of doxycycline for 1G4WT (or 2H5WT) and b (or z) mutants were used in order to achieveCell Reports 36, 109375, July 13, 2021 e8
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normalizing for unequal (6V-A2)4 binding. Cells were then labeled with 50 nM CellTrace violet (Thermo Fisher) or with carrier control
DMSO (Sigma). CellTrace labeling did not interfere with proximal signaling events. To measure TCR surface expression a surface
staining with AF647-conjugated UCHT1-Fab’ fragment was performed according to the protocol described in Flow cytometry pro-
cedures before the stimulation assay. For this, labeled and unlabelled cells were mixed 1:1 and washed once before being re-sus-
pended at 203 106/ml in RPMI without FBS pre-warmed at 37C. Cells were then distributed at 0.53 106 cells/well (25 ml) in a 96-well
V-bottom plate (Eppendorf) and equilibrated at 37C for 10 min in a ThermoMixer C (Eppendorf). 1:2 dilution series of 2X (6V-A2)4-PE
or (MART-1-A2)4-PE were added directly to the wells to a final concentration of 600 to 0.78 nM and 50 to 0.05 nM, respectively. After
stimulation (pz: 60 s, pErk: 180 s) an excess of fixation buffer (BD Cytofix) was added and samples fixed for 10 min at 37C. Samples
were permeabilised and stained intracellularly with AF647-conjugated anti-pErk (1:50) or with AF647-conjugated anti-pY142z (1:5) as
described in Flow cytometry procedures. Samples were acquired on a CyAn ADP (Beckman Coulter) or BD LSR Fortessa X20 (BD
Bioscience) as specified. Raw data was analyzed by FlowJo (FlowJo software, part of BD) and MFIs were extracted from FlowJo as
excel files. Further analysis and statistical tests were performed with Prism (GraphPad Software). For pz-dose-response the back-
ground subtractedMFIs of pzwere plotted against the background subtractedMFI of tetramer (6V-A2)4-PE binding and fitted by non-
linear regression ([Agonist] versus response - three parameters). The background subtracted values of MFIs of pz with the highest
dose of (6V-A2)4-PE (400 nM) were normalized to WT or left as pairs and tested for significance with a t test (paired or unpaired
respectively). For pErk-dose-responses, pErk MFIs were background subtracted and plotted against the dose of (6V-A2)4-PE or
(MART-1-A2) 4-PE and fitted by non-linear regression ([Agonist] versus response - Variable slope (four parameters) or [Agonist]
versus response - three parameters) or fitted to a minimal model of kinetic proofreading signaling (see Mathematical modeling sec-
tion). In both non-linear regression fits, no constrains were applied and the expected best-fit values of maximum pErk for WT
and mutant were analyzed for significance with the F-test. The same procedure was used to evaluate max. pErk response upon
(6V-A2)4-PE titration, in J76 CD8
+ 1G4 zKO expressing zWT and zmutants (zA38, zA41).
PMA stimulation
To evaluate maximal pErk potential of J76 CD8- 1G4 WT or bA291, cells were labeled with 50 nM CellTrace violet (Thermo Fisher) or
with carrier control DMSO (Sigma), mixed 1:1 and washed once before being re-suspended at 203 106/ml in RPMI without FBS pre-
warmed at 37C. Cells were then distributed at 0.53 106 cells/well (25 ml) in a 96-well V-bottom plate (Eppendorf) and equilibrated at
37C for 10 min in a ThermoMixer C (Eppendorf). 1:2 dilution of 2X PMA (Phorbol 12-myristate 13-acetate, Sigma) and Ionomycin
(Sigma) was added directly to the wells to a final concentration of 66.6 ng/ml and 2 mg/ml, respectively. After stimulation (180 s)
an excess of fixation buffer (BD Cytofix) was added and samples fixed for 10 min at 37C. Samples were permeabilised and stained
intracellularly with AF647-conjugated anti-pErk (1:50) according to the protocol described above. Raw data was analyzed by FlowJo
(FlowJo software, part of BD) andMFIs were extracted from FlowJo as excel files. Further analysis and statistical test were performed
with Prism (GraphPad Software). The background subtracted values of MFIs of pErk for WT and bA291 were exported and mean
values of each experiment, measured in triplicates, were normalized toWT. Statistical significancewas tested by unpaired t test using
Prism (GraphPad Software).
Basal z-phosphorylation
J76 CD8+ 1G4 WT or bA291 cells were induced for TCR expression with 1 mg/ml doxycycline at 0.3 3 106 cells/ml. Cells were har-
vested at 24, 48, 72 or 96 h and processed immediately for FACS analysis of CD3 surface expression or intracellular pz according to
the protocol described in Flow cytometry procedures. As staining for CD3 surface expression with an anti-CD3ε induced signaling
even when carried out at 4C using precooled solutions, samples were split in two and one part was stained for surface CD3 at 4C
while the other part was fixed at 37C, permeabilised and analyzed for basal pz. Samples were acquired on a CyAn ADP (Beckman
Coulter). Raw data was analyzed by FlowJo (FlowJo software, part of BD) andMFIs were extracted from FlowJo as excel files. Further
analysis and statistical tests were performed with Prism (GraphPad Software). pz MFI was normalized to CD3 MFI (pz/CD3), mean
values of each experiment were normalized to WT or left as pairs and significance was tested by t test (unpaired or paired
respectively).
Sm-pMHC binding to cells
To detect non-specific adsorption of sm-pMHC onto J76 cell membrane during the stimulation assay (see Soluble monovalent-
pMHC stimulation section) CD8-deficient wtc51 J76 were induced or not for TCR expression with 1 mg/ml doxycycline for 48 h,
labeled with 50 nM CellTrace violet (Thermo Fisher) or with carrier control DMSO (Sigma), mixed 1:1 and washed once before being
re-suspended at 103 106 in 125 mL of pre-warmed RPMI at 37C. Cells were then distributed in a 96-well V-bottom plate (Eppendorf)
and equilibrated at 37C for 10min in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm). Dilution series of 2X sm-9V-A2
were added directly to the wells to a final concentration of 400 to 0.2 nM as indicated in the plot. After 5 min of binding, samples were
rapidly centrifuged at 4C, washed with 100 mL of ice-cold FACS-buffer and stained with APC-conjugated anti-HLA-A2 (1:100) for
20 min on ice to detect sm-9V-A2 bound to cells as described in Flow cytometry protocols. Samples were acquired on BD LSR For-
tessa X20 (BD Bioscience). Raw FACS data for TCR-deficient and TCR-efficient J76 were analyzed in FlowJo (FlowJo Software) and
MFI of APC-anti-HLA-A2were extracted as excel files. Further analysis and statistical tests were performed in Prism (GraphPad Soft-
ware). The MFI of the APC-anti-HLA-A2 binding was corrected for background, plotted against the concentration of sm-9V-A2 and




To fit the tetramer binding data, we used an effective 1:1 binding model:
C = Bmax  ½TetramerðKd + ½TetramerÞ
where Bmax is the maximum binding and Kd is an effective binding constant. We found that this model was able to fit both theWT and
mutant TCR data. Importantly, we found that a single value of Kd was sufficient to fit both dataset or equivalently, we found no ev-
idence to reject the null hypothesis that tetramer binding was identical to both (F-test, p = 0.066).




Kd + ½Tetramer 
kp
ðkp+ koffÞN
where the first term determines tetramer occupancy (fraction between 0 and 1) and the second term determines the probability of
signaling, kp the forward rate of proofreading, N the number of steps, and koff the unbinding rate.
Given that we found no evidence for a difference in binding (see above), we asked whether a difference in the proofreading rate (kp)
can explain the difference in the pErk data. To do this, we simultaneously fit both the WT and mutant TCR pErk data to the mathe-
matical model with a different value of kp for each TCR. As above, we fit a single value of Kd for both datasets and in this model, we
fixed the value of koff to the experimentally determined value (0.85 s
-1; Aleksic et al., 2010) and fixed the value of N to the recently
reported value (Tischer and Weiner, 2019; Yousefi et al., 2019). This is reasonable since we do not expect the TCR mutation to alter
the number of steps.
We found that this model was able to produce an excellent fit to the data. Importantly, we found that a single value of kp could not
explain the pErk data or equivalently, we had sufficient evidence to reject the null hypothesis that a single value of kp could explain the
data (F-test, p < 0.0001).
Biochemical analysis of the TCR-CD3 complex
SDS-PAGE, immunoblotting and quantitation
SDS-polyacrylamide gel electrophoresis (PAGE) was performed using the protein electrophoresis system from Bio-Rad (Bio-Rad)
according to the manufacturer’s instructions. Custom-made 15% polyacrylamide gels were used and proteins separated at 100 V
in TGS (Tris Glycine SDS) running buffer (Bio-Rad). Separated proteins were transferred onto nitrocellulose membranes (Trans-
blot Turbo Transfer Pack, Bio-Rad) using the Trans-blot turbo transfer system (Bio-Rad). As a routine, the High-MW protocol (25
V, 2.5 A, 10 min) or the Standard protocol (25 V, 1 A, 30 min) were used for the transfer. Membranes were saturated in blocking buffer
(TBS, 0.1% Tween-20, 3%BSA) for 30 - 60min at RT with gentle shaking and incubated overnight at 4C or 1 h at RT with the primary
Ab diluted (see Key resources table for a list of the Abs used in this study) in blocking buffer. After 3 washes of 10 min each with wash
buffer (TBS-T), membranes were incubated with IRDye 800 CWor IRDye 680 CW (LI-COR) secondary Ab in blocking buffer for 45min
at RT in the dark. The membrane was then washed twice for 10 min with wash buffer (TBS-T) and once with wash buffer without
Tween-20 in order to remove residual detergent and reduce the background during the acquisition. Near-Infrared (NIR) Western
Blot Quantitative Detection was performed using the Odyssey CLx system (LI-COR) and the images were quantified using the Image
Studio Lite software. The signal of each band was calculated as median - local background, intended as the signal detected in the
area surrounding the band analyzed. The signal values were exported as excel files for relative quantification.
DDM TCR-CD3 stability assay
Cells (103 106/sample) were counted, centrifuged once at 425 x g, transferred to a 1.5 mL tube with RPMI 0% FBS and washed with
cold PBS. The cell pellet was lysed with 150 mL of ice-cold lysis buffer (150 mM NaCl, 20 mM Tris, pH 8.0 containing 0.5 or the indi-
cated % of n-Dodecyl b-D-maltoside (DDM) (Millipore), 1X protease inhibitors (cOmplete, EDTA free, Roche), 1 mM Sodium Ortho-
vanadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated 30 min on ice. 0.5%
DDM was chosen as it is the highest concentration of detergent compatible with maximal recovery of CD3 ε and z associated
with ab, in contrast, increasing concentration of DDM from 1% to 4% gradually decreased CD3 recovery, affecting z more than ε
(Figure S2A and data not shown). These data agreed with the recent cryo-EM structure (Dong et al., 2019) that shows zz to be
the dimer most loosely associated to the rest of the complex. Lysates were centrifuged 10 min at 16,100 x g at 4C and 15 mL of
the post nuclear supernatant were saved for input control. The rest of the supernatant was transferred in a new tube containing
10 mL of anti-HA-conjugated agarose beads (Sigma) pre-washed 3 times with 1 mL of lysis buffer. One sample was transferred to
a tube containing anti-HA-conjugated agarose beads pre-washed and pre-saturated for 2 h at 4C under constant rotation with
50 mg/ml of HA peptide (Sigma), to assess background. Protein complexes were pulled down by incubating the supernatant and
the anti-HA-conjugated agarose beads for 1 h at 4C under constant rotation. Beads were centrifuged for 30 s at 2,500 x g and
washed 3 times with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant was carefully removed and the beads re-sus-
pended in 20 mL 1X NuPAGE LDS Sample Buffer (Invitrogen) containing or not (see below) 1X NuPAGE Sample Reducing Agent (In-
vitrogen) and incubated at 70C for 10 min. After cooling, beads were centrifuged for 30 s at 2,500 x g and the supernatant wasCell Reports 36, 109375, July 13, 2021 e10
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OPEN ACCESScollected in a fresh tube, loaded on a 15% polyacrylamide gel at 4C and processed as described above (SDS-PAGE, immunoblot-
ting and quantitation). The results were analyzed and presented as follow: for each sample, the background subtracted signals of ε, g,
d and zwere normalized to b and the obtained ratios (ε/b, g/b, d/b and z/b) were normalized to WT. Statistical unpaired t test analysis
was performed using Prism (GraphPad Software). To evaluate gε and dε recovery to ab, the supernatant from a single pull down was
split in two, loaded in duplicates on a 15% polyacrylamide gel and immunoblotted for either b (HA), g, ε and z or b (HA), d, ε and z.
Moreover, to minimize the interference of the IgG light chain of the anti-HA, used to pull down b, with the detection of d and g (mo-
lecular weight 20 - 25 kDa), at the end of the procedure described above, the beads were re-suspended in 20 mL 1X NuPAGE LDS
Sample Buffer (Invitrogen) without adding reducing agent, but rather adding Iodoacetamide (Sigma) to a final concentration of
20 mM, an alkylation agent used to block thiols of proteins. Iodoacetamide was present in all the buffers used in this specific pull
down (lysis buffer and sample buffer).
For endoglycosidase H (endo H) treatment, protein complexes were eluted by re-suspending the beads in 22 mL of lysis buffer con-
taining 1X Glycoprotein Denaturing Buffer (NEB) and incubating at 100C for 10min. Beads were centrifuged for 30 s at 2,500 x g, the
supernatant was collected, divided in two fresh tubes and 1X buffer 3 (NEB) was added in presence or not of endo H (750 U) for 1 h at
37C. Samples were then incubated at 70C for 10min with 1X NuPAGE LDS Sample Buffer (Invitrogen) containing 1XNuPAGE Sam-
ple Reducing Agent (Invitrogen) and loaded on a 15% polyacrylamide gel at 4C and processed as described above (SDS-PAGE,
immunoblotting and quantitation).
zTST pull-down
J76 CD8+ 1G4 zKO expressing inducible zTST were treated with 1 mg/ml doxycycline overnight, counted and washed once with
150 mL of ice-cold PBS. Pellets of 103 106 cells were lysed with 150 mL ice-cold lysis buffer (150 mM NaCl, 20 mM Tris, pH 8.0 con-
taining 0.5% n-Dodecyl b-D-maltoside (DDM) (Millipore), 1X proteases inhibitors (cOmplete, EDTA free, Roche), 1 mM Sodium Or-
thovanadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated on ice for 10 min.
Lysates were centrifuged for 10min at 16,100 x g at 4C and 15 mL of the post nuclear supernatant was collected as a control for total
input. The rest of the supernatant was transferred into a fresh tube containing 10 mL Strep-Tactin Sepharose beads (IBA Lifesciences)
pre-washed with lysis buffer and incubated for 30 min at 4C under constant rotation. Alternatively, the supernatant was incubated
30 min at 4Cwith anti-HA-conjugated agarose beads (Sigma). One sample was transferred to a tube containing Strep-Tactin beads
or anti-HA-conjugated agarose beads pre-washed and pre-saturated for 2 h at 4C under constant rotation with 50 mM biotin or
50 mg/ml of HA peptide respectively, to assess background. Beads were centrifuged for 30 s at 2,500 x g and washed 3 times
with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant was carefully removed and the beads re-suspended in
20 mL 1X NuPAGE LDS Sample Buffer (Invitrogen) containing 1X NuPAGE Sample Reducing Agent (Invitrogen) and incubated at
70C for 10 min. After cooling, beads were centrifuged for 30 s at 2,500 x g and the supernatant was collected in a fresh tube before
being separated on a 15%polyacrylamide gel at 4C.Quantitative immunoblotting with anti-HA and anti-zmAbswere used to identify
the b isoform interacting with z among the three identified in the total b pull-down performed using anti-HA-conjugated agarose
beads.
Ligand-induced TCR-CD3 quaternary structure changes
Resting or pMHC-stimulated TCR-CD3
The structural integrity of the TCR-CD3 complex upon (9V-A2)4 and sm-9V-A2 stimulation of intact cells at physiological temperature
or at 0C was evaluated by the following assay. J76 CD8+ or CD8- cells expressing inducible TCR wtc51 were treated with 1 mg/ml
doxycycline overnight, counted and washed once with RPMI without FBS. Cells were re-suspended at 103 106/150 mL in the same
medium and pre-incubated for 10 min at 37C in a ThermoMixer C (Eppendorf) under constant shaking (500 rpm) or 20 min on ice.
(9V-A2)4 obtained using a His-tagged streptavidin (His-SA) (100 nM), sm-9V-A2 (200 nM) or RPMI alone was added to the cells for
5 min at 37C or on ice. After ligand binding, the samples were immediately centrifuged 30 s at 800 x g and rapidly washed once with
150 ml of ice-cold PBS. For Lck inhibition, cells were pre-treated with 5 mMA770041 (Axon) at 37C for 20 min prior to stimulation and
5 mMA770041was kept during the binding. Cell pellets were lysedwith 150 mL ice-cold lysis buffer (300mMNaCl, 20mMTris, pH 8.0
containing 0.5% n-Dodecyl b-D-maltoside (DDM) (Millipore), 1X proteases inhibitors (cOmplete, EDTA free, Roche), 1 mM Sodium
Orthovanadate (NEB), 10mMSodium Fluoride (Sigma), 25 U/ml Benzonase Nuclease (Millipore) and 10mM Imidazole and incubated
on ice for 5 min. Lysates were centrifuged for 5 min at 16,100 x g at 4C and 15 mL of the post nuclear supernatant was collected as a
control for total input. The rest of the supernatant was incubated 5min on icewith 1 mg of His-tagged streptavidin (sm-9V-A2 engaged
samples) or transferred directly into a fresh tube containing 10 mL HisPur Cobalt Resin (Thermo Fisher) ((9V-A2)4 engaged samples) or
10 mL anti-HA-conjugated agarose beads (Sigma) (non-stimulated samples), pre-washed with lysis buffer and incubated for 15 min
and 30 min respectively at 4C under constant rotation. To assess background, one sample was transferred to HisPur Cobalt beads
or anti-HA-conjugated agarose beads pre-washed and pre-saturated at 4C for 2 h under constant rotation with 300mM Imidazole or
50 mg/ml of HA peptide respectively. Beads were centrifuged for 30 s at 2,500 x g and washed 3 times with 1 mL of ice-cold lysis
buffer. After the last wash, the supernatant was carefully removed and the beads re-suspended in 20 mL 1X NuPAGE LDS Sample
Buffer (Invitrogen) without reducing agent and incubated at 80C for 5 min. After cooling, beads were centrifuged for 30 s at 2,500 x g
and the supernatant was collected in a fresh tube and incubated at 80C for 5 min with 1X NuPAGE Sample Reducing Agent
(Invitrogen). Samples were separated on a 15% polyacrylamide gel at 4C and processed as described above (SDS-PAGE, immu-
noblotting and quantitation). Quantitative immunoblotting with anti-HA and anti-zmAbs were used to evaluate the amount of b and ze11 Cell Reports 36, 109375, July 13, 2021
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OPEN ACCESSpulled-down in each condition. The amount of z extracted at steady state was normalized to a specific b isoform (b2) that we proved
to be the only one able to interact with the z chain (for details see in zTST pull down) and that corresponds to the only detectable
isoform in (9V-A2)4-engaged receptor pull downs (for schematic of the procedure see Figures S6A and S7A). The value for z/b2 ratio
from non-stimulated samples was set equal to one. This value represented the recovery of intact TCR-CD3 complex and was
compared to z/b2 from (9V-A2)4 stimulated samples. Statistical analysis using unpaired t test was performed using Prism (GraphPad
Software).
To isolate sm-9V-A2-engaged wtc51 with monomeric avidin agarose beads (Thermo), cells were incubated with sm-9V-A2
(200 nM) or RPMI alone for 5 min at 37C. After ligand binding, the samples were lysed as described above and the post-nuclear
supernatant was incubated with monomeric avidin beads for 30 min at 4C under constant rotation.
For primary CD8 T cells expressing constitutive TCR wtc51, cells were incubated for 5 min at 37C with (9V-A2)4 obtained using a
His-tagged streptavidin (His-SA) (40 nM), 9V-A2 (400 nM) or RPMI alone. Lysis was performed in presence of 30 mM imidazole and
this concentration was maintained during the following washes.
Isolation of (6I-A2)4 and sm-6I-A2 engaged receptors in J76 CD8
+ cells expressing 868 TCR (Kd = 50 nM) was performed as
described above with little variations. Cells were incubated with (6I-A2)4 obtained using a His-tagged streptavidin (His-SA)
(40 nM), sm-6I-A2 (400 nM) or RPMI alone for 5 min at 37C. Lysis was performed in the presence of 30 mM imidazole and this con-
centration was maintained during the following washes.
To have a comparable amount of b detected by immunoblotting in non-stimulated samples and (6I-A2)4 and sm-6I-A2 engaged
samples, only 1/3 of the elution from non-stimulated samples was loaded on the gel.
Isolation of (9V-A2)4 engaged receptors in J76 CD8
+ cells expressing inducible QM-a TCR (Kd = 140 nM) was performed as
described above with little variations. Cells were incubated with (9V-A2)4 obtained using a His-tagged streptavidin (His-SA)
(333 nM), or RPMI alone for 5 min at 37C. Lysis was performed in the presence of 30 mM imidazole and this concentration
was maintained during the following washes. Elution was performed by incubating the beads at 4C for 15 min with 15 mL of lysis
buffer containing 300 mM imidazole. Beads were then centrifuged for 30 s at 2500 x g and the supernatant was collected in a fresh
tube and incubated at 80C for 5 min with 1X NuPAGE LDS Sample Buffer containing 1X NuPAGE Sample Reducing Agent
(Invitrogen).
To have a comparable amount of b detected by immunoblotting in non-stimulated samples and (9V-A2)4 engaged samples, only
1/40 of the elution from non-stimulated samples was loaded on the gel.
Soluble monovalent-pMHC stimulation
Intracellular triggering upon soluble monovalent agonist (sm-pMHC) binding was evaluated by pErk activation, according to the
following procedure. J76 CD8+ or CD8- cells expressing 868 or wtc51 TCRs (the latter induced for TCR-CD3 expression
with 1 mg/ml doxycycline for 48 h) were counted and washed once with RPMI without FBS. Cells were re-suspended at
103 106/125 mL in the same medium and pre-incubated for 10 min at 37C in a ThermoMixer C (Eppendorf) under constant shaking
(500 rpm). For Lck inhibition, cells were pre-treated with 5 mM A770041 (Axon) at 37C for 15 min prior to stimulation and 5 mM
A770041 was kept during the binding. Tetramers (pMHC4,25 nM), sm-pMHC (100 nM) or RPMI alone were added to the cells for
5 min at 37C. After ligand binding, samples were immediately boiled for 10 min at 95C by adding pre-warmed 2X NuPAGE LDS
Sample Buffer (Invitrogen) containing 2X NuPAGE Sample Reducing Agent (Invitrogen) to instantly stop the reaction. Cell lysates
were let cool down and 25 U of Benzonase Nuclease (Millipore) were added every 15 min for 4 times to allow a complete DNA/
RNA digestion. Lysates were centrifuged for 15 min at 16,100 x g at 4C and supernatant was collected in a fresh tube before being
separated on a 15% polyacrylamide gel. Quantitative immunobloting with anti-pErk and anti-actin was used to evaluate the amount
of Erk phosphorylation (for details, see SDS-PAGE, immunoblotting and quantitation). The value for pErk (-background)/actin ratio
from non-stimulated samples was set equal to one. Statistical analysis using unpaired t test was performed using Prism (GraphPad
Software).
To exclude that the observed signaling (pErk) was the consequence of surface cell-to-cell ligand cross-presentation, we used the
above protocol (also used for the evaluation of sm-pMHCbinding by FACS, see sm-pMHCbinding to cells section) with cells express-
ing or not TCR. Briefly, CD8-deficient wtc51 J76 not induced for TCR expression were counted, washed once with RPMI, re-sus-
pended at 103 106/125 mL in the samemedium and pre-incubated for 10min at 37C in a ThermoMixer C (Eppendorf) under constant
shaking (500 rpm). Sm-9V-A2 (200 nM) or RPMI alone was added to the cells for 5min at 37C, rapidly washed with ice-cold RPMI (to
minimize unbinding), re-suspended in pre-warmedRPMI at 103 106/125 mL and added to an equal amount of dox-inducedCD8-defi-
cient wtc51 J76 for 5 min at 37C. After ligand binding cells were immediately boiled for 10 min at 95C by adding pre-warmed 2X
NuPAGE LDS Sample Buffer (Invitrogen) containing 2X NuPAGE Sample Reducing Agent (Invitrogen) to instantly stop the reaction
and cell lysates were analised as described above.
UCHT1-Fab’ or UCHT1 Ab-engaged TCR-CD3
The structural integrity of the TCR-CD3 complex upon agonist stimulation of intact cells at physiological temperature or at 0C was
evaluated by the following assay. The anti-CD3ε mAb UCHT1 was used as a potent agonist of TCR-CD3 and its Fab’ as the non-
agonist control that binds to the same determinant. J76 CD8+ cells stably expressing 1G4 TCR were counted and washed once
with RPMI without FBS. Cells were re-suspended at 10 3 106/150 mL in the same medium and pre-incubated for 10 min at 37C in
a ThermoMixer C (Eppendorf) under constant shaking (500 rpm) or for 20 min on ice. Mono-biotinylated Fab’ of UCHT1 mAb
(0.72 mg) or biotinylated UCHT1 intact mAb (2 mg) (BioLegend) was added to the cells for 5 min at 37C or on ice. These dosesCell Reports 36, 109375, July 13, 2021 e12
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OPEN ACCESSof anti-CD3ε ligands that corresponded to approximately the same molarity were proven to pull-down similar amounts of TCR-
CD3 complex, as detected by ε immunoblot. One sample was left untreated as negative control. After ligand binding, the samples
were immediately centrifuged 30 s at 800 x g and rapidly washed once with 150 mL of ice-cold PBS. For Lck inhibition, cells were
pre-treated with 5 mM A770041 (Axon) at 37C for 20 min prior to binding of Fab’ UCHT1 or UCHT1 mAb and 5 mM A770041 was
kept during the binding. Cell pellets were lysed with 150 mL ice-cold lysis buffer (150 mM NaCl, 20 mM Tris, pH 8.0 containing
0.5% n-Dodecyl b-D-maltoside (DDM) (Millipore), 1X proteases inhibitors (cOmplete, EDTA free, Roche), 1 mM Sodium Orthova-
nadate (NEB), 10 mM Sodium Fluoride (Sigma) and 25 U/ml Benzonase Nuclease (Millipore) and incubated on ice for 30 min. Ly-
sates were centrifuged for 10 min at 16,100 x g at 4C and 15 mL of the post nuclear supernatant was collected as a control for
total input. The rest of the supernatant was transferred into a fresh tube containing 10 mL Streptavidin Sepharose High Perfor-
mance beads (GE Healthcare) pre-washed with lysis buffer and incubated for 1 h at 4C under constant rotation. Beads were
centrifuged for 30 s at 2,500 x g and washed 3 times with 1 mL of ice-cold lysis buffer. After the last wash, the supernatant
was carefully removed and the beads re-suspended in 20 mL 1X NuPAGE LDS Sample Buffer (Invitrogen) containing 1X NuPAGE
Sample Reducing Agent (Invitrogen) and incubated at 70C for 10 min. After cooling, beads were centrifuged for 30 s at 2,500 x g
and the supernatant was collected in a fresh tube before being separated on a 15% polyacrylamide gel. Quantitative immunoblot-
ing with anti-ε, anti-HA and anti-z mAbs was used to evaluate the amount of ε, b and z, respectively, pulled-down after each stim-
ulatory condition (for details, see SDS-PAGE, immunoblotting and quantitation). The recovery of ε was assumed to be invariant in
both the stimulatory (UCHT1 mAb) and non-stimulatory (UCHT1-Fab’) condition and was used for the normalization of the
amounts of the other subunits in each pull-down. Therefore, the values for b/ε and z/ε ratios obtained from UCHT1-Fab’ engaged
TCR-CD3 were set equal to one. These values represented the recovery of intact TCR-CD3 complex and were compared to the
same ratios from UCHT1 stimulated samples. Statistical analysis using unpaired t test was performed using Prism (GraphPad
Software).
Microscopy
dSTORM imaging and analysis
Prior to dSTORM imaging, cells were plated on glass m-slide 8-wells chamber (Ibidi) coated with recombinant human ICAM-1 protein
(R&D Systems) at 2.5 mg/ml concentration. Cells were incubated for 15minutes at 37C followed by fixation for 30min with 4%PFA at
RT. Cells were blockedwith 5%BSA in PBS for 1 h followed by incubation with an anti-CD3 primary antibody directly conjugatedwith
Alexa Fluor 647 (BioLegend) for 1 h at RT. Cells were washed three times with PBS and post-fixed with 4% PFA for 5 min before im-
aging.CysteaminebaseddSTORM imagingbufferwasused toperform the singlemolecule localization experimentswith the following
composition: 100 mM Cysteamine MEA (Sigma Aldrich), 5% Glucose (Sigma Aldrich), 1% Glox (0.5 mg/mL glucose oxidase, 40 mg/
mL catalase (Sigma Aldrich) dissolved in 1X PBS. dSTORM imaging of CD3 was performed by using a 1503 1.45-NA oil-immersion
objective in TIRFmode (TIRF;Olympus). Laser light of 642nmwasused to excite theAlexa Fluor 647dyeand switch it to thedark state.
An additional 405 nm laser light was used to reactivate the Alexa Fluor 647 fluorescence. The emitted light from Alexa Fluor 647 was
collected by the same objective and imaged by an EMCCD camera (Evolve Delta; Photometrics) at a frame rate of 10ms per frame. A
maximumof 5,000 frames per conditionwere acquired. dSTORM imageswere analyzed and rendered as previously described (Bates
et al., 2007; Huang et al., 2008) using a custom-written software (Insight3, provided by B. Huang, University of California, San Fran-
cisco). Peaks in single-molecule images were identified based on a threshold and fit to a simple Gaussian to determine the x and y
positions. Only localizations with photon count > 400 photons were included, and localizations that appeared within one pixel in
five consecutive frames were merged together and fitted as one localization. The final images were rendered by representing the x
and y positions of the localizations as a Gaussian with a width that corresponds to the determined localization precision. Sample drift
during acquisition was calculated and subtracted by reconstructing dSTORM images from subsets of frames (500 frames) and corre-
lating these images to a reference frame (the initial time segment).
Pair auto-correlation analysis
Pair auto-correlation analysis is independent of the number of localizations and is not susceptible to over-counting artifacts related to
fluorescent dye re-blinking (Stone et al., 2017). Auto-correlation analysis of CD3 protein was performed usingMATLAB software pro-
vided by Sarah Shelby and Sarah Veatch from University of Michigan. Regions containing cells were masked by a region of interest,
and the auto-correlation function from the x and y coordinate list from the 642 nm dSTORM channel was computed from these re-
gions using an algorithm described previously (Shelby et al., 2013; Stone et al., 2017; Veatch et al., 2012).
DBSCAN cluster analysis
Quantitative cluster analysis was based on Density-based spatial clustering of applications with noise (DBSCAN) (Ester et al., 1996).
The DBSCAN method detects clusters using a propagative method which links proteins belonging to the same cluster based on the
minimum number of neighbors ε (ε = 7) in the radius r (r = 25 nm). Clus-DoC (Pageon et al., 2016) MATLAB based software with im-
plemented DBSCAN analysis was used. The x and y coordinate list of dSTORM localizations was used and regions containing cells
were selected to give the mean ± SD value of CD3 cluster size per cell.
Fluorescent Recovery after Photobleaching (FRAP) and analysis
Prior to FRAP experiment, cells were incubated for 20 minutes at 37C with an anti-CD3 primary antibody directly conjugated
with Alexa Fluor 647 (BioLegend). Cells were washed with cell media and seeded on glass m-slide 8 well chamber (Ibidi)
coated with Poly-L-Lysine for 5 min before imaging. Cysteamine based dSTORM imaging buffer was used to perform thee13 Cell Reports 36, 109375, July 13, 2021
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OPEN ACCESSexperiments (see dSTORM imaging and analysis). FRAP imaging of CD3 was performed by using a Nikon A1R HD25 confocal
system with a 60x oil-immersion objective (Nikon, UK) in humidified 37C, 5% CO2 chamber. A circular region was defined on the
surface of the cell. This region was bleached using the 405 nm laser with maximum power for 7 s. Before and after bleaching, the
whole region was visualized by 640 nm laser for the duration of 50 s in 4 s intervals. FRAP curves were exported from NIS-
Elements software (Nikon, UK) and the post processing of the extracted curves was performed in Origin software (OriginPro
2017; OriginLab).
Atomistic Molecular Dynamics Simulations
The transmembrane region (TMR) of the T cell receptor (TCR) was extracted from the cryo-EM structure PDB: 6JXR (Dong et al.,
2019) and used for atomistic molecular dynamics simulations. The residues of TCRb TMR are numbered according to that used
in our experiments (‘‘n - 1’’ compared to PDB: 6JXR, i.e., our bY291 is bY292 in 6JXR). The TMR sequences used are shown in Table
S3. The octameric protein structure was inserted in a complex asymmetric bilayer (lipid concentration is shown in Table S4) using
CHARMM-GUI (https://charmm-gui.org) and was solvated with TIP3 water molecules. The lipid types and their concentrations in
our simulated bilayer were considered from studies on the T cell membrane conducted by Zech et al. (2009). The system was
then neutralized with a concentration of 150 mM of NaCl ions. The resultant molecular system and molecular dynamics parameters
were obtained from CHARMM-GUI and thereafter run using Gromacs 2016.4 (Van Der Spoel et al., 2005) using the CHARMM36
forcefield (Lee et al., 2016). An energy-minimization of the entire system was conducted for 5000 steps using the steepest descent
algorithm. The energy-minimized system underwent a 6-step NPT equilibration where position restraints on the protein backbone,
side-chain and lipids were gradually released. The LINCS algorithm (Hess et al., 1997) was used to apply constraints on bond lengths.
The fully equilibrated system was used to generate starting points for 3 production simulation repeats with different initial velocities.
This was done for the wild-type complex, zA38, zA41 and bA291 mutants which started from the same initial configuration. Each
production simulation was run for 1250 ns employing a 2 femtoseconds time-step and the co-ordinates were saved every 40 pico-
seconds. The Nose-Hoover thermostat (Hoover, 1985) was used with a reference temperature of 323 K and coupling constant of 1
picosecond. The Parrinello-Rahman barostat (Parrinello and Rahman, 1981) was used with a semi-isotropic pressure coupling type,
reference pressure of 1 atmosphere, compressibility value of 4.53 105 bar-1 and coupling constant of 5 picoseconds. The Particle
mesh Ewald algorithm (Essmann et al., 1995) with a 12 Å distance cut-off was used to define non-bonded van der Waals (Lennard-
Jones) and coulombic interactions. Visualization was carried out using VMD (Humphrey et al., 1996). Protein-protein interaction pro-
files and spatial distribution plots are a result of merged data from all the 3 repeats of all-atom simulations. To calculate the spatial
distribution of zz relative to ab, the positions of Ca atoms of abwere fixed throughout the simulation time. The spatial distributions of
Ca atoms of zz and ab are viewed from the extracellular region.
Modeling of the 1G4 TCR affinity mutants
The 1G4-A2-SLL structure (from PDB: 2BNR) (Chen et al., 2005) was used to model the 1G4 QM-a-A2-SLL and 1G4 wtc51-A2-SLL
tri-molecular complex structures. Sequences were adjusted with COOT (Emsley and Cowtan, 2004) and graphical representations
and analysis were prepared with PYMOL (DeLano, 2002; Available: https://pymol.org/2/).
QUANTIFICATION AND STATISTICAL ANALYSIS
Flow cytometry
All experiments were replicated at least two - three times with technical and/ or biological replicates each time. Raw data was
processed in FlowJo (FlowJo software, part of BD) and MFIs, counts or percentages were extracted from FlowJo as excel files.
Statistical analysis and non-linear regression fitting were performed with Prism (GraphPad Software). Significance was assessed
by two-tailed paired or unpaired t test. Non-linear regressions were tested for Goodness of Fit (R2), for normality (D’Agostino &
Pearson omnibus normality test) and with the replicates test. Non-linear regression fits are specified in the methods paragraph
describing the experimental procedure. R2 and p-value for the fits, significance tests and significance are indicated in the figure
or figure legend.
Pull-down and Immunoblotting
Experiments were replicated at least two - three times with technical and/ or biological replicates each time as indicated at the rep-
resenting figure. Raw data was extracted from Image studio (LI-COR Biosciences) and processed in Excel and Prism (GraphPad
Software). Statistical analysis (two-tailed unpaired t test) was performed and method and significance are indicated in the figure
or figure legend.
Microscopy
Samples were tested for normality with a Kolmogorov–Smirnov test. The statistical significance of differences between two
datasets was assessed by a two-tailed t test assuming unequal variance. All statistical analysis was performed using Origin software




For the atomistic simulations multiple repeat simulations were performed to ensure reproducibility of our results. Analyses of the sim-
ulations were conducted using Gromacs, VMD, and locally written code.
Modeling
Graphics and analysis were prepared with PYMOL (DeLano, 2002; Available: https://pymol.org/2/).
Significance
* p % 0.05 /** p % 0.01/*** p % 0.001/**** p % 0.0001/ ns = not significant.e15 Cell Reports 36, 109375, July 13, 2021
